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ABSTRACT 
Streptococcus pneumoniae, known as the pneumococcus, remains the leading cause of mortality 
and morbidity worldwide in children <5 years due to pneumonia, with the highest burden of 
disease in developing countries. The pneumococcus is responsible for a variety of diseases, from 
localised infections such as otitis media and sinusitis, to life-threatening diseases such as 
meningitis and pneumonia.  
 
The polysaccharide capsule, exterior to the cell wall, is the major virulence factor of the 
organism. To date, 93 different capsular types, called serotypes, have been described. These 
differ in their chemical structures, and <15% of serotypes are responsible for majority of 
pneumococcal disease worldwide. Some serotypes have a higher invasive potential than others, 
while some are associated with more severe outcome than others. There is also a geographic and 
age-specific variation in the distribution of serotypes. Pneumococcal diseases are largely vaccine 
preventable. The current vaccine formulations contain serotypes that are most prevalent across 
regions. The licensed polysaccharide and polysaccharide conjugate vaccines (PCV) contain at 
least 23 and 10 or 13 of most prevalent serotypes, respectively. Serotypes that were historically 
not commonly associated with invasive pneumococcal disease (IPD) are increasing in prevalence 
due to the reduction of vaccine serotypes. Thus, it is important to monitor serotype distribution 
for future vaccine formulations and to determine the vaccine effectiveness in the region. 
 
The “gold standard” for serotyping, the Quellung reaction, is dependent on the viability of the 
organism, and hence it is problematic in settings where a culture cannot be obtained due to 
insensitivity of blood cultures, incorrect culturing techniques, initiation of antibiotic therapy 
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before the specimen is taken or autolysis of the pneumococcus. Although molecular methods 
have been established to identify pneumococcus as the disease-causative agent, serotyping was 
not possible on culture-negative samples until recently. Sequencing of the capsular biosynthetic 
loci of >90 serotypes revealed conserved regions and serotype-specific genes, which serve as 
targets for the PCR-based assays.  
 
In this study, PCR-based serotyping assays were established in South Africa (SA) for culture-
negative samples initially by using isolates of known serotypes. The conventional PCR assay (C-
PCR) showed 100% sensitivity (801/801) and specificity (29/29) for serotypes included in the 
assay when compared with the Quellung reaction. However, specificity of the real-time PCR 
serotyping assay (RT-PCR) was 95% (89/94) compared to the Quellung reaction and the C-PCR 
assay, due to cross-reactions between genetically related serotypes/serogroups. The prevalent 
disease-causing serotypes were detected in the first three reactions of the C-PCR assay and first 
four reactions of the RT-PCR serotyping assay, allowing for the majority of isolates to be 
assigned a serotype in a time-efficient manner.  
 
While both C-PCR and RT-PCR serotyping assays had comparable sensitivities on samples with 
sufficient DNA concentration, RT-PCR had an increased sensitivity in assigning serotypes for 
clinical specimens and non-viable transport medium samples (NVTMs). These samples often had 
a lytA cycle threshold (Ct) values of >26, indicative of low bacterial loads/DNA concentration. In 
2010, 4201 cases of IPD were reported to the national IPD surveillance laboratory in SA. Viable 
isolates were not available for 10% (n=440) of all cases reported and 395 were available for 
serotyping. Of these, 80% (173/217) of NVTMs and 91% (162/178) of culture-negative clinical 
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specimens could be assigned a serotype using the PCR-based methods. The PCR-based assays 
added 8% (335/4201) of serotyping data to the national surveillance database for 2010. The 
newly discovered serotype 6D was not identified in SA in 2010. 
 
The establishment of PCR-based serotyping assays was useful in the monitoring of serotype-
specific disease burden. The prevalent serotypes in all SARI (severe acute respiratory illness) 
cases were 19A, 1 and 6A/B. This data is useful for determining the effectiveness of the 7-valent 
pneumococcal conjugate vaccine (PCV7) effectiveness in children with known vaccination status. 
The PCR-based serotyping assays could assign a serotype to 95% (18/19) of the pleural fluids 
positive for lytA received as part of an empyema study. Serotypes 6A/B (n=8, 44%), 19A (n=3, 
17%), 23F (n=3, 17%), 14 (n=2, 11%) and 1 (n=2, 11%) were prevalent in these specimens.  
 
PCV13 serotypes 19A and 1 were prevalent in cultures and culture-negative samples included in 
this study, suggesting the potential increased positive public health impact offered by introduction 
of 13-valent PCV in SA in 2011. PCR provided important serotyping data on a significant 
proportion of culture-negative samples. A number of culture-negative samples were positive for 
PCV7 serotypes, and therefore these data are useful for monitoring vaccine impact on serotype 
distribution. Thus, the burden of disease and the serotype distribution can be monitored 
effectively for vaccine failures and future vaccine developments, in a cost-effective and timeous 
manner  
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1 Introduction 
1.1 Background 
Streptococcus pneumoniae, or the pneumococcus, is a commensal of the human upper respiratory 
tract with the highest colonisation rates observed in children <5 years of age [1]. It is an 
aerotolerant anaerobic Gram-positive diplococcus appearing in chains in a liquid medium. It is 
soluble in bile salts, α-haemolytic on blood agar medium and susceptible to optochin (ethyl 
hydrocuprein). However, resistance to optochin and other microbial agents have been observed in 
rare strains of the pneumococcus [2;3]. Haemolysis on blood agar medium is due to the 
breakdown of haemoglobin in blood agar resulting in greenish colonies.  
 
This organism has historically played a central role in the field of microbiology. The 
identification of DNA as being the genetic carrier was first discovered through the pneumococcus 
[4]. Avery et al discovered that the pneumococcus can take up foreign DNA and incorporate it 
into its genome, thereby conferring a new phenotype with the characteristics of the foreign piece 
of DNA [4]. This concept is known as bacterial transformation and is now applied globally in 
many cloning experiments and other scientific research. The concept of antibiotic resistance was 
first observed in the pneumococcus in 1912 using optochin [5;6]. The principle of the Gram stain 
was discovered in 1881 using the pneumococcus and is the most important bacterial 
characterisation test used in microbiology [5;6].  
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1.2 Pneumococcal diseases 
Apart from colonising the nasopharynx of healthy individuals, S. pneumoniae is a significant 
human pathogen. The reason for changing from the colonisation state to the invasive state 
remains unclear [7]. S. pneumoniae can cause invasive diseases such as meningitis and 
bacteraemia, as well as non-invasive diseases such as non-bacteraemic pneumonia, otitis media, 
sinusitis and bronchitis [1;8] (Figure 1). The pneumococcus is a leading cause of community-
acquired pneumonia (CAP) [9-11] and meningitis. The pneumococcus is also the leading cause of 
empyema, described as an accumulation of pus in the pleural cavity. The organism is responsible 
for more than 1 million deaths per year among children <5 years of age worldwide, with the 
highest burden in developing countries such as in African and Asian countries [12]. Pneumonia 
causes more deaths than malaria, AIDS and measles combined [11]. 
 
Figure 1. Clinical syndromes of pneumococcal disease classified according their frequency, with 
IPD being represented by a small fraction as bacteraemia and meningitis. The red vertical bars 
indicate syndromes that could result in death [13]. 
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1.2.1 Risk factors for pneumococcal disease 
S. pneumoniae is transmitted through inhalation of aerosols from an asymptomatic carrier or 
diseased individual [14]. IPD affects mostly children <2 years of age and the elderly [1;15;16]. 
Individuals who have underlying conditions e.g. cardiovascular diseases or chronic liver diseases, 
or are immunocompromised, are at increased risk of IPD and disease in such patients is 
associated with greater severity and complications [17-19]. Due to reduced clearance of 
encapsulated bacteria in persons with anatomical or functional asplenia (absence of spleen or 
non-functional spleen) [18;20], people with this condition are at greatest risk of pneumococcal 
infections associated with high mortality rates. Children attending day-care centres [21;22], 
persons in prisons, old-age homes or people living in clustered and disadvantaged communities 
are at higher risk for IPD and carriage [23;24]. In vaccinated children, risk factors for both 
carriage and IPD due to vaccine and non-vaccine serotypes includes absence of breastfeeding, 
exposure to smoke, presence of underlying sickness and male gender [17].  
1.3 Diagnosis of pneumococcal diseases 
Culture is the diagnostic gold standard; however, it is dependent on the growth of the organism. 
For culture-negative clinical specimens, PCR-based detection of pneumococcal DNA can be used 
for diagnosis. PCR has shown to be useful in diagnosing pneumococcal disease in patients who 
have already started antibiotic treatment [25]. Antibiotic usage reduces the yield of blood 
cultures, which are dependent on viable bacteria. PCR is not dependent on the viable bacteria, 
and can detect DNA from a non-viable microorganism following antibiotic treatment. Regions of 
the lytA gene, coding for autolysin, are specific to the pneumococcus and can be used for 
detection of the pneumococcus in a clinical specimen [26-28]. The quantitative real-time PCR 
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(RT-PCR) assay can also be used to determine the bacterial load, which is associated with the 
severity of disease [25;29;30]. Thus patients with high pneumococcal bacterial loads are more 
likely to have more severe disease at time of specimen collection than patients with low bacterial 
loads. 
 
Aetiological diagnosis of the causative agent of bacterial pneumonia, also known as severe acute 
respiratory illness (SARI), remains a challenge due to inadequate diagnostic tests. A new method 
being investigated for the diagnosis of pneumococcal pneumonia in patients with respiratory 
illness is the RT-PCR detection of lytA in blood specimens of patients presenting with symptoms 
of pneumonia [31]. Molecular methods detecting pneumococcal DNA in the blood specimens of 
patients has been shown to serve as a useful marker for pneumococcal pneumonia [29;32]. Azzari 
et al [33;34] employed a technique in which the diagnostic lytA RT-PCR and the conventional 
serotyping PCR were aimed to target two different genes for specificity purposes i.e. the lytA 
gene in RT-PCR and the cpsA gene in the serotyping assay. Thus, if both reactions were positive, 
then the confidence of the diagnosis was enhanced [33;34]. 
1.4 The polysaccharide capsule 
The pneumococcal capsule is one of the major virulence factors of the organism [7]. The capsule 
is a polysaccharide structure made up of repeating sugar units. The structure is external to the cell 
wall and it provides resistance to phagocytosis by the host cells and aids in the evasion of the host 
immune system [35]. The capsule was first discovered in 1880, by Sternberg and Pasteur, who 
also were the first to isolate this micro-organism, and named it Diplococcus pneumoniae [36].  
The pneumococcal polysaccharide capsule is highly diverse. A number of genetic events have 
resulted in the diversity of the polysaccharide synthesis loci such as point mutations, deletions, 
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insertions, duplication, and divergent evolution [37]. Pneumococci can produce at least 93 
distinct capsules that differ in their chemical structure; and are called serotypes [38-40]. The 
capsular polysaccharide synthesis genes (cps) encode for different saccharides that makes up the 
repeating units. More than one serotype can be found within the same capsular group (serogroup) 
with differences within the biosynthetic locus due to recombinational events. Historically, 
serotypes were numbered as types according to how commonly they were isolated in disease 
episodes i.e. Serotype 1, 2 and serotype 3 were named as such because it was the most prevalent 
serotype isolated in disease episodes and associated with high mortality [41].  
1.4.1 The capsular polysaccharide synthesis (cps) locus 
In 2006, the capsular biosynthetic loci of all 90 serotypes available then were genetically 
analysed [38]. All the genes within the polysaccharide capsular locus were sequenced for the first 
time to determine the diversity between serotypes. The cps loci of all serotypes are flanked by 
dexB and aliA genes on the 5` and 3` ends respectively, and all other genes are oriented in the 
same direction as the dexB and aliA genes. The first four genes of the biosynthetic loci i.e. wzg, 
wzh, wzd and wze are conserved in all serotypes, whereas the central genes are serotype-specific 
genes [38] (Figure 2). The cps loci key enzymes were found to be highly diverse, consisting of 
highly diverse transferases, 40 homology groups for polymerases, and 13 homology groups for 
flippases [38]. Serotype 1 is the only case where the cps loci lack initial transferases encoding 
genes [38;42].  
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Figure 2. An example of the cps loci from four selected serotypes showing the conserved 
flanking regions at the ends, the four conserved genes in blue and the hypervariable regions in the 
middle of the capsular locus [38].  
 
The availability of the cps sequences and the polysaccharide structures (CPS structures) enabled 
studies of genetic relatedness between the cps loci to be performed [42]. Eight pneumococcal 
clusters and 21 sub-clusters from 88 serotypes were assigned based on their genetic similarities. 
Serotypes within the same serogroup were grouped into the same cluster except for serotypes 
within serogroups 7, 16, 17, 33, 35 and 47. Serotypes were classified in the same cluster or sub-
cluster if they shared a dominant epitope, irrespective of other major differences in other parts of 
the cps [38]  
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I. Cluster 1 
This cluster consists of one sub-cluster comprising of serotypes 12F, 44, 12B, 12A and 46. 
Serotypes 12F and 12A are highly similar, differing only by an initial sugar and a side branch. 
Serotypes 44 and 46 have the same synteny as serogroup 12, differing only in the transposase 
genes. The relatedness between these serotypes suggests a common ancestry. Serotypes 44 and 46 
cross-react with factor sera 12b/12d and 12d respectively. Serotypes 4 and 5 are also grouped in 
this cluster, although they show minor similarities to the other serotypes in this cluster, but share 
a dominant epitope [38;42].  
II. Cluster 2  
This cluster is comprised of 40 serotypes grouped into 12 sub-clusters, all containing the 
rhamnose biosynthesis genes as the dominant epitope, with an exception of serotype 1 and 24B 
due to mutations.  
Serogroup 6 
Serotypes 6A and 6B are highly similar, differing by a sugar linkage due to a point mutation. 
Serotype 6C, which was discovered in 2007 [43], differs from serotype 6A by the presence of 
glucose residue as the second sugar in the repeating unit compared to a galactose residue in 
serotype 6A as the second sugar of the repeating unit [42].  
Serogroup 7 
This serogroup is comprised of two sub-clusters. Serotypes 7A and 7F are grouped into the same 
sub-cluster, while serotypes 7C, 7B and 40 form the second sub-cluster. Serotype 40 is closely 
related to serotypes 7C and 7B than to serotypes 7A and 7F. Serotypes 7A and 7F differ only by 
the side branch available in 7F, but not 7A due to frame-shift mutations [38;42] 
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Serogroup 17 
Serotypes 17A and 17F are found in this serogroup. Apart from sharing a dominant epitope, these 
serotypes are less similar, clustered into two different sub-clusters. Serotype 17F is sub-clustered 
with serogroups 24 and 48. There is a high similarity between serotypes 24B and 24F, as 
compared to serotype 24A. Two unique genes are only found in the cps loci of serogroups 24, 
17F and 48 [42]. Serogroup 17 serotypes are grouped together because of sharing the most 
important genes e.g. initial transferase [and the central genes [42], although belonging to different 
sub-clusters.  
Serogroup 18 
All serogroup 18 serotypes fall into one sub-cluster. Serotypes 18B and 18C differ only by two 
base substitutions [38]. Serotype 18F has an additional acetyltransferase gene compared to 
serotypes 18B and 18C, and in serotype 18A, the acetyltransferase gene is absent. Apart from the 
differences in the linkage structures, the CPS structures of these serotypes are almost identical, 
with the major difference being in serotype 18A [42].  
Serogroup 19 
Serotypes 19A, 19B, 19C and 19F belong into the same sub-cluster and the CPS structures of all 
serogroup 19 serotypes have been studied intensively. Serotypes 19F and 19A are closely related, 
differing only in the polymerisation linkage between the glucose and rhamnose sugars [42;44]. 
Switching from serotype 19F to serotype 19A capsule production is highly possible by replacing 
only two genes within serotype 19A cps locus [44]. Serotype 19C has an additional glucose side 
chain compared with all other serogroup 19 serotypes. The gene rearrangements within the 
central region of the serogroup 19 cps loci have led to the emergence of four highly 
distinguishable serotypes (Figure 3).  
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Figure 3. Capsular polysaccharide synthesis loci of serogroup 19 serotypes showing the central 
hyper-variable regions responsible for divergence of serogroup19 serotypes [44]. 
 
Serogroup 22 
Serotypes 22A and 22F are highly similar, forming one sub-cluster. Although serologically 
distinguishable, the chemical differences on the CPS structures between the two serotypes is yet 
to be determined [42].  
Serogroup 23 
All serogroup 23 serotypes belong to one sub-cluster. Serotypes 23A, 23B and 23F differ in their 
polymerisation linkages [42]. 
Serogroup 28 
Due to the cross-reactions in the immunological assay, serotypes 28F, 28A and serotype 16F are 
grouped into the same sub-cluster [42]. The cps locus of serotype 16F is highly similar to 
serogroup 28, and less similar to serotype 16A, which belongs to a different sub-cluster [42].  
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Serogroup 32 
Serotypes 32F, 32A and 27 capsular biosynthetic loci are classified under one sub-cluster. 
Serotypes 27 and 32 cps loci only differ at the central regions, while the 5` and the 3` ends are 
highly similar. Serogroup 32 cross-reacts with factor sera 27b. Serotypes 32A and 32F differ only 
in the acetylation patterns [42]. 
Serogroup 41 
Serotypes 41A, 41F, 31, and 17A, are closely related, forming a sub-cluster. Serotypes 41F and 
41A differ only at the 3` end by having two different non-functional genes. Serogroups 31 and 41 
cps loci differ only at the acetylations and initial transferases genes. Serotypes 17A and 41F are 
highly similar at both ends, forming similar linkages at the 5` and the 3` ends.  
III. Cluster 3 
The immunological cross reactivity between serotypes 25A, 25F and 38, and the similarities in 
their cps loci warranted a single sub-cluster for these serotypes. Serotypes 25A and 25F loci are 
highly similar, and only differ to serotype 38 in one gene which is truncated in serogroup 25 and 
not truncated in serotype 38. Serotypes 25F and 38 cross-react with factor sera 25b, while factor 
sera 38a cross-reacts with serotypes 25A and 38 in the immunological reactions [42].  
IV. Cluster 4 
Four sub-clusters are found in this cluster, constituting 23 serotypes. These serotypes are mostly 
similar at the 3` end of the cps loci 
Serogroup 10 
Serogroup 10 consists of serotypes 10A, 10B, 10C and 10F, which are all sub-clustered together. 
Serotypes 10A and 10B are more similar to each other, lacking an acetyltransferase gene, while 
the gene is present in serotypes 10C and 10F [42]. 
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Serogroup 33 
Serogroup 33 serotypes form three syntenic pairs, which are not found in the same sub-cluster. 
Serotypes 33A and 33F differ only by a frame-shift mutation in the acetyltransferase gene, and 
they belong to one sub-cluster. Serotypes 33B and 33D form a separate sub-cluster and are 
similar. Serotype 33C is not similar to any of the serogroup 33 serotypes, and it is classified alone 
in a separate sub-cluster [42].  
Serogroup 35 
Serotypes of serogroup 35 are classified into three different sub-clusters. Factor sera 35a cross-
reacts with all serotypes of serogroup 35 in immunological reactions. Serotypes 35A, 35C and 42 
are found in the same sub-cluster, and factor sera 35c cross-reacts with the three serotypes found 
in this sub-cluster. There is a strong resemblance in the central region of the cps locus of serotype 
35B and serotype 29, forming a separate sub-cluster, and factor sera 29b cross-reacts with these 2 
serotypes. Serotype 35F is highly similar to serotype 47F, constituting a third sub-cluster with a 
difference in the phosphate transferase gene [42].  
Serogroup 47 
Apart from serotype 47F, serotype 47A is found in a different sub-cluster. Serotype 47A is more 
similar to serotype 43 than to serotype 47F [42].  
V. Cluster 5 
The serotype 8 biosynthetic locus is highly divergent, and it is the only serotype found in this 
sub-cluster. Previous studies showed that serotype 8 might have originated from serotype 33F, 
due to the sequence similarities at the 3` end of the cps loci [45]. 
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VI. Cluster 6 
All serogroup 9 serotypes falls within this cluster, forming one sub-cluster with two branches. 
Serotypes 9V and 9A have the same synteny while serotypes 9L and 9N are highly similar [42] 
Although these serotypes are an example of divergence from a single cps locus, the sequences of 
the two pairs are highly dissimilar [38]. Serotypes 9A and 9V differ only in the acetylation 
patterns, with serotype 9V having an O-acetylation not present in the other serogroup 9 serotypes. 
In serotype 9A, the gene responsible for the O-acetylation was disrupted by a frame-shift 
mutation. Serotype 9N differs from 9L by having a glucose rather than galactose as residue 3. 
Serotypes 9A and 9V have an insertion element, which is not present in serotypes 9N and 9L 
[38].  
VII. Cluster 7 
The five serotypes of serogroup 11 i.e.11A, 11B, 11C, 11D and 11F form one sub-cluster, 
grouped into two syntenic groups. Serotypes 11F, 11A and 11D are grouped together, while 
serotypes 11B and 11C belong to the second group. As in serogroup 9, these serotypes are an 
example of divergence from a common ancestor. The main difference between the five serotypes 
is in the acetyltransferase genes. Serotypes 11F, 11A, and 11D have two extra acetyltransferase 
genes, while 11F and 11A genes only possesses one extra acetyltransferase gene [42]. 
VIII. Cluster 8 
This cluster contains two sub-clusters comprised of serogroup 15 serotypes in one cluster, and 
serotype 14 forming a second sub-cluster [42]. The CPS structures of serogroups 15 and 14 are 
highly similar, differing at the 3` end of the capsular biosynthetic loci. However, no cross-
reaction between the two serogroups had been observed in the serological reactions. Serotypes 
15B and 15C form linear structures, while serotypes 15A and 15F are branched due to the 
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polymerisation patterns [38]. Serotype 14 resembles serotypes 15B and 15C more than serotypes 
15A and 15F [42]. 
1.4.2 Role of polysaccharide capsule in invasive disease 
The capsular type of each individual strain plays a role in its ability to cause invasive disease. 
Heavily encapsulated isolates e.g. serotype 19F and 23F are more resistant to clearance by the 
host and are mostly involved in carriage. Thus, there is an inverse relationship between heavy 
encapsulation and invasiveness [46-48]. However, heavily encapsulated serotypes may be highly 
lethal should they invade. In addition, some serotypes e.g. serotypes 4 and 5 are rarely isolated 
from carriage compared to disease episodes [47]. Some serotypes are associated with a higher 
case-fatality ratios than others e.g. serotypes 3, 6A, 6B, 9N and 19F whereas serotypes 1 and 14 
are associated with low case-fatality ratios [48]. Pneumococcal clones of the same serotype can 
have different invasion capacities, indicating that the polysaccharide capsule is not the only factor 
contributing to virulence [49].  
 
Although there are 93 serotypes described to date, only a small fraction of these cause most cases 
of invasive disease worldwide [50]. There is geographical variation in the distribution of 
pneumococcal serotypes, although the most common serotypes are found globally e.g. serotype 
6B. Serotype 1 is predominant in Africa and in older children [15;50-52]. Certain serotypes are 
associated predominantly with disease in children or adults while others are associated with a 
specific syndrome. Serotype 14 and serotype 1 are more commonly isolated from bacteraemia 
cases whereas serotypes 6A/6B, 10A/B and 23F are more commonly associated with meningitis 
[53].  
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1.5 Phenotypic serotyping 
Pneumococcal serogroup and serotype identification can be performed by various phenotypic 
antibody-antigen based methods, mostly involving large panels of antisera, such as the Quellung 
reaction, latex agglutination, co-agglutination, the dot blot assay, enzyme-linked immunosorbent 
assay, and counterimmunoelectrophoresis [27;54;55].  
1.5.1 The Quellung reaction 
The Quellung reaction (“swelling” in German), which is considered the “gold standard” for 
serotyping of the pneumococcus was first described by Neufeld in 1902. It refers to the refractive 
property of the pneumococcal capsule when exposed to homologous antibodies [56]. The method 
involves mixing equal amounts of the antiserum and pneumococcal suspension and fixing it on a 
glass slide. The cells are then viewed under a phase-contrast microscope to detect swelling of the 
capsule. For clear visualisation, methylene blue dye is added on the cover slip before covering the 
slides. A positive agglutination will result in the capsule doubling in its size, and this swelling is 
visible under the phase-contrast light microscope (Figure 4) [56]. A simplified method for the 
Quellung reaction was developed, whereby a group to which an isolate belongs is detected by 
pooled antisera, and then if positive for a certain group, the isolate is tested for all serotypes 
belonging to that group. The most prevalent serotypes responsible for IPD are included in one 
group, and in this manner, the most commonly occurring serotypes can be detected first [27;57]. 
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Figure 4. A phase-contrast microscopic image at 100X magnification illustrating the positive 
Quellung reaction for pneumococcus with the swollen capsule indicated by the purple colour 
around the diplococcus, using methylene blue stain. 
 
To date, the Quellung method uses sera including the omni-, pool-, type-, and factor sera, which 
cover >90 capsular types of pneumococci [58]. The omni serum contains all the antibodies for 
>90 serotypes, and is used to confirm encapsulation. An omni-negative isolate implies a non-
typeable pneumococcus or that the isolate is not S. pneumoniae. In the latter case, other biological 
tests such as solubility in bile salts and Gram stain, for identification of the pneumococcus are 
used. 
 
The major disadvantages of the Quellung reaction method are the high cost of antisera, the 
requirements for technical skills, the complexity in interpretation of the results and the 
unsuitability for large-scale serotyping. Another major limitation of this method is that it is 
dependent on the viability of the organism. It is therefore not useful in cases of culture-negative 
clinical specimens. Specimens may be culture negative due to a number of reasons, such as the 
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use of antibiotics prior to the patient presenting to the hospital and incorrect handling/storage and 
transportation of the specimens.  
1.5.2 Latex agglutination 
Latex agglutination, developed in 2004 [27], was shown to be promising as an alternative to the 
Quellung reaction because of its simplicity and the fact that the results could be obtained rapidly. 
The method involves mixing the pneumococcal broth culture with the pooled antisera on a glass 
slide and within seconds, the results are readable by the naked eye. The disadvantage of this 
method is that it can only detect pooled serogroups, and the Quellung reaction is still needed to 
determine serotype within the serogroup [54].  
1.5.3 Monoclonal antibody-based serotyping  
Monoclonal antibody-based serotyping e.g. the multibead assay, employs flow cytometry using 
monoclonal antibodies and latex beads with pneumococcal polysaccharides covalently linked to 
the beads. The method was the basis for discovery of serotypes 6C and 11E [39;43]. The 
technique poses a challenge in the development of antibodies, technical experience required and 
the cost involved [54]. However, it is very specific and with the generation of more antibodies, 
new serotypes that are misclassified by the available typing methods could be discovered.  
1.6 Molecular serotyping 
The sequences of the cps loci from 90 serotypes have been completed by the Sanger Institute 
(UK) in 2006 [59], thereby providing the opportunity to develop a sequence-based scheme for 
identifying pneumococcal serotypes. PCR primers designed from the central variable regions of 
the capsular biosynthetic loci are the basis of molecular serotyping.  
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1.6.1 The conventional sequential multiplex PCR assay  
A conventional sequential multiplex PCR, referred to as conventional PCR (C-PCR) assay was 
developed at the Centers for Disease Control and Prevention (CDC) in Atlanta, US [60]. The 
initial assay detected only 29 serogroups/types while more recently the protocols have been 
updated to detect at least 40 serogroups/types [61;62]. The reactions are arranged such that the 
most commonly occurring serotypes in the US and African regions are detected within the first 
few reactions. At least five or six serotypes are detected in each reaction and an internal control 
for pneumococcal encapsulation is included in all reactions in the assay (Figure 5). The serotypes 
selected cover a wide range of IPD-causing serotypes, and different protocols are available for 
regions with varying serotype distributions.  
 
Pai et al were able to serotype 96% (401/421) of their isolates using the protocol for targeting 
only 29 serogroups/types. The results were in agreement with the results of the Quellung reaction. 
The remaining 20 isolates could not be assigned a serotype either because they were a rare 
serotype not included in the assay or they were non-typeable [60]. The method has been used 
successfully in many countries with minor adaptations to the multiplex reactions used at the CDC 
[63-65]. The method was used directly on clinical specimens from a DNA-containing supernatant 
of clinical specimens (after centrifugation) and the yield of serotypes determined was 90% 
compared to 40% from the Quellung reaction [66]. Multiplex PCR-based serotyping has proven 
to be cost effective, rapid, and less laborious than the Quellung reaction and can be employed 
successfully for culture-negative specimens [67]. The Quellung reaction can be used to 
supplement the multiplex PCR for serotypes not included in the PCR assay.  
Chapter 1. Introduction 
18 
 
To limit the number of multiplex PCR reactions, only the most prevalent serotypes are included 
in the assay. Thus, one limitation is that the rarely occurring serotypes are not detected. Another 
limitation is that for some serotypes which have highly similar sequences, the primer sequences 
cannot distinguish individual serotypes, and only a serogroup can be obtained e.g. serogroup 
18B/C or serotype 38/25F [60]. The internal control (cpsA) that is currently used to confirm 
encapsulation is also not reliable for <2% of encapsulated pneumococci especially serotypes 38 
and 25, so the absence of the cpsA band does not equate to a non-typeable pneumococcus [62]. 
The presence of the serotype band without a cpsA control band is considered a positive serotype. 
However, the problem arises in culture-negative samples where the Quellung reaction cannot be 
used due to lack of a culture, and therefore the serogroups would remain unresolved. 
Identification of a serotype within a serogroup or a cluster can be epidemiologically important, in 
cases where the one serotype is in one of the conjugate vaccine formulations and the other is not, 
e.g. 18C is in the PCV7 formulation, while 18B is not. The inability to differentiate these 
serotypes is an epidemiological challenge for vaccine effectiveness studies. However, the 
complexity and the cost of the Quellung reaction still make PCR a useful alternative. 
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Figure 5. An illustration of agarose gels for the six multiplex reactions showing the serotypes 
included in each reaction (shown on the bottom of each figure), covering the 33 serotypes 
detected by the C-PCR assay developed by the CDC. The cpsA control is pointed out in reaction 
3 and 6. M indicates the molecular weight marker used for assigning product sizes [68].  
1.6.2 Real-time PCR serotyping assay 
The sensitivity of molecular serotyping is increased by the use of RT-PCR, which is more 
sensitive than C-PCR [33;67]. The advantage of RT-PCR is the speed in obtaining the results. 
RT-PCR does not require downstream processing of PCR products as in conventional PCR, as 
products are detected on a real-time basis [69]. It is also useful for detection of low DNA 
concentration samples, due to its high sensitivity. However, the assay is more expensive than 
conventional PCR due to the cost of equipments and reagents used e.g. probes. A number of RT-
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PCR assays for pneumococcal serotyping have been described [34;70-72]. Tarrago et al [70] 
developed a RT-PCR assay for serotyping of the pneumococcus in culture-negative specimens 
that are positive for pneumococcal DNA. The assay was validated using isolates of known 
serotypes from the Quellung reaction, and there was a 100% specificity obtained. The assay 
targets only sixteen serogroups/types and this selection covered 80.9% of their invasive isolate 
serotypes in ten reactions (consisting of a combination of singleplex and duplex reactions).  
 
Azzari et al [34] developed an assay to cover 21 serotypes and were able to serotype 100% 
(38/38) of their isolates, and 91% (61/67) of their clinical specimens. The assay consists of 21 
singleplex reactions, detecting serogroups/types 1, 3, 4, 5, 6, 7A/F, 8, 9V/A, 10A/B 12A/B/F, 14, 
15, 18B/C, 19A, 19B/F, 20, 22A/F, 23F, 33A/F, 35B, and 38. These serotypes, excluding 
serogroup 38, are part of the 23-valent polysaccharide vaccine and are included in the current 
PCV formulations i.e. PCV7, PCV10 and PCV13. This assay has been used successfully in Italy 
where 92% (73/80) of pneumococcal-positive whole blood specimens could be serotyped [73]. 
An additional multiplex RT-PCR serotyping assay for detecting 13 serotypes in four reactions 
(three multiplex reactions and 1 singleplex reaction) has been described [71] and 50% (5/10) of 
the culture-negative specimens were assigned a serotype.  
 
A potential disadvantage of the multiplex RT-PCR assays is loss of sensitivity in the multiplex 
format, therefore for optimum results, all 21 reactions should be carried out individually or in 
duplex reactions. The sensitivity of the RT-PCR assays was not reduced in the duplex reactions 
and multiplex reaction formats developed for detection of respiratory viruses [74;75], and this is 
needs to be explored further for the pneumococcus.  
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1.7 Serotype distribution in South Africa 
There is a strong association between HIV status and serotype distribution amongst children and 
adults in SA [76-79]. In 1995, serogroups 6, 23, 14 and 19 were more commonly isolated from 
HIV-negative children while in HIV-infected children, serogroups 23, 14 and 6 were the 
prevalent serogroups isolated. Serogroups 6, 14, 19, and 23, commonly known to be paediatric 
serotypes were isolated from HIV-positive adults in 1993-1995, indicating that 
immunocompromised adults are more susceptible to infection with paediatric serotypes [78-80]. 
Serotype 1 is prevalent in HIV-infected and HIV-uninfected adults [79].  
 
In SA, from 1991-1998, an increase in serogroup 19 was observed whereas all the other common 
serotypes remained stable in children ≤2 years [78]. Serotypes 6A/B remained the leading IPD-
causing serotypes in children <5 years. Young adults are at increased risk of IPD due to serotype 
3, compared to other age groups [81]. From 2008-2010, annual reports of the Group for Enteric, 
Respiratory and Meningeal Disease Surveillance in SA (GERMS-SA) showed that the same 
mentioned serotypes, which were common a decade earlier, were still prevalent in 2010 [82]. The 
common serotypes isolated in SA (2008-2010) from children <5 years from viable isolates are 
serotypes 14, 6B, 23F, 6A, 19F, 19A and 1 [82]. 
1.8 Pneumococcal vaccines 
1.8.1 Pneumococcal polysaccharide vaccines 
The majority of disease due to S. pneumoniae is vaccine preventable. The 23-valent 
pneumococcal polysaccharide vaccine, (Pneumovax
®
; Merck & CO, Whitehouse station, NJ, 
USA and Pnu – immune®, Lederle Laboratories, Pearl river, NY, USA) containing serotypes 1, 2, 
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3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F,19A, 20, 22F, 23F and 33F 
was licensed for use in 1983 in the US [18;83;84]. This vaccine replaced the previously licensed 
14-valent pneumococcal polysaccharide vaccine licensed in 1977 [85]. The 23 serotypes covered 
85-90% of serotypes that were responsible for IPD in US in 1978-1995 for all age groups and that 
were associated with drug resistance [18;83]. The capsular antigens elicit an immune response of 
type-specific antibodies enhancing the opsonisation and phagocytosis of pneumococci of these 
specific serotypes.  
 
The 23-valent polysaccharide vaccine is recommended for individuals >65 years of age as well as 
individuals from 2 to 64 years of age who are at high risk for acquiring pneumococcal disease e.g. 
immunocompromised individuals, people living in special environments like old-age homes and 
prisons [84;86;87]. This vaccine reduced IPD in the vaccinated immunocompetent individuals as 
well as people with underlying conditions such as diabetes [84]. The vaccine elicits a poor or no 
immune response in children <2 years of age due to lack of activation of T-cell immunity in 
young children whose immune systems are immature. Children <2 years of age and 
immunocompromised individuals of all ages are incapable of mounting a T-cell dependent 
immune response to the polysaccharide antigens in the vaccine [88]. The vaccine does not 
provide mucosal immunity and only protects against IPD caused by the serotypes in the vaccine 
[89]. 
 
In SA, Pneumovax
®
 23 (Merck) available from 1992 has been replaced by Imovax Pneumo 23
® 
(Sanofi Pasteur SA, Lyon, France). Utilization of this vaccine is low in SA compared to other 
countries [76].  
Chapter 1. Introduction 
23 
 
1.8.2 Pneumococcal conjugate vaccines 
An immune response to polysaccharides vaccines can be improved by covalently bonding the 
polysaccharide to a protein carrier such as diphtheria toxin, CRM 197 (cross-reactive protein). 
The protein carrier activates the T-cell dependent pathway of the immune response thereby 
enabling young children to elicit an immune response to these vaccines. A disadvantage of 
polysaccharide conjugate vaccines is that only a limited number of antigens can be linked to a 
protein carrier. 
 
The 7-valent pneumococcal conjugate vaccine, PCV7 (Wyeth Pharmaceuticals, Inc., 
Philadelphia), containing serotypes 4, 6B, 9V, 14, 18C, 19F and 23F was licensed for use in 
children <5 years of age in the US in 2000 [88]. There has subsequently been a significant decline 
in IPD caused by vaccine and vaccine-related serotypes in the targeted age group [90;91]. Similar 
trends of the reduction of IPD due to vaccine serotypes were observed in other areas where the 
vaccine was implemented such as England [92], Spain [93] Canada [94] and Western Australia 
[95]. It reduces acquisition and carriage of vaccine and vaccine-related serotypes by providing 
mucosal immunity [96;97]. 
 
In addition, PCV7 has caused a significant decrease in IPD and carriage in the unvaccinated 
community due to indirect protection, known as the “herd effect” [91;96-98]. The herd effect is 
due to the reduction in carriage of vaccine and vaccine-related serotypes in immunised children, 
which, in turn causes a reduction in carriage and pneumococcal disease in the elderly who have 
not been immunised [98]. The reductions in IPD due to vaccine and vaccine-related serotypes 
were consistent in the US across all sites and in all age groups where the conjugate vaccine was 
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implemented, supporting the high effectiveness of the vaccine, irrespective of socio-economic 
status [99]. Similar trends have been observed in other countries where the conjugate vaccine is 
routinely used [8;92;96;100;101]. 
 
Moreover, there was a decline in pneumonia hospitalisation rates subsequent to PCV7 
introduction in the US [102-104]. In 2005-2006, rates of pneumococcal pneumonia cases had 
declined from 25.9 to 13.4 and from 144.9 to 64.7 cases per 100 000 population <1 years and ≥65 
years, respectively [103]. These reductions in pneumococcal pneumonia were also observed in 
unvaccinated age groups due to herd effect.  
 
In countries like Canada, Korea, Argentina, Brazil and some European countries [105-107], 
PCV7 has been replaced by a 10-valent conjugate vaccine (PHiD-CV10; Synflorix, GSK, Inc., 
Belgium) based on the results of immunogenicity studies without clinical trials [107]. The 
serotypes included in PCV10 are PCV7 serotypes and additional serotypes 1, 5 and 7F. New 
pneumococcal conjugate vaccines can be licensed based on comparable immunogenicity and 
safety to the already licensed vaccine, as recommended by the World Health Organization 
(WHO) [108], as in the licensure of PCV10. The 13-valent pneumococcal conjugate vaccine 
(PCV13; Prevnar 13, Wyeth Pharmaceuticals Inc., Philadelphia, marketed by Pfizer Inc.) was 
first introduced in Chile in July 2009. The serotypes included in PCV13 are PCV10 serotypes and 
additional serotypes 3, 6A and 19A. PCV9 (PCV7 serotypes plus serotypes 1 and 5) and PCV11 
(PCV9 plus serotypes 3 and 7F) have been used in clinical trials [109;110] and have shown 
efficacy in reducing pneumococcal diseases [111;112]. Clinical trials in SA and the Gambia 
showed a significant reduction in radiologically-confirmed pneumonia by 17% and 37% in all 
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children, respectively, attributed to PCV9 [109;113]. PCV9 was not licensed because of the close 
similarity to PVC7 and was superseded by PCV13 [114], while PCV11 was not licensed due to 
reduced immunogenicity response when co-administered with other vaccines in the infant 
immunisation schedule [115].  
 
PCV13 was introduced in the US in the routine immunisation programme for the same age group 
in February 2010 to replace PCV7. High immune responses to the PCV13 serotypes were 
observed in the immunogenicity studies done, except for serotype 1, which elicited poor antibody 
responses for unknown reasons [116]. Developing countries such as Guyana, Kenya, Yemen, 
Congo, Sierra Leone have introduced PCV13 in 2011 as part of the GAVI (Global Alliance for 
Vaccines and Immunisation) global pneumococcal vaccine roll-out [117]. Individuals aged 
between 2 and 18 years at high risk for pneumococcal infections who had received all doses of 
the conjugate vaccine/s are recommended to have PPSV23 as a booster dose [15;116]. Moreover, 
recently in December 2011, PCV13 was approved for people ≥50 years of age in the US to 
further reduce the burden of pneumococcal diseases in the elderly in addition to the herd effect 
observed [118]. 
 
In SA, PCV7 was introduced (April 2009) into the Expanded Programme on Immunisation (EPI), 
for all children <2 years of age with a 6- and 14-week dose schedule, followed by a booster at 9 
months [119]. PCV13 was introduced into the EPI programme in SA from May 2011 to replace 
PCV7. The schedule is the same as used for PCV7, with a catch-up dose at 18 months for 
children who received 2 or 3 doses of PCV7 or all children <2 years. However, by June 2011, 
only few provinces and health-care facilities had switched to PCV13. 
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In SA, HIV is endemic and pneumococcal infections are associated with HIV seropositivity in 
both children and adults [76;113]. Moreover, HIV seropositivity is associated with an increased 
penicillin and multi-drug resistance in pneumococci [79]. In South African children, there was a 
42-fold increase IPD incidence rates in HIV-infected compared to uninfected children from 1997-
1999 [120]. The increased risk of IPD in HIV-infected children was sustained even in the era of 
highly active antiretroviral therapy (HAART) [77]. Similar high incidence rates were observed 
among Mozambican children; where the incidence rates of pneumonia hospitalisations were 
between 9.3-19.0-fold higher in HIV-infected children than in HIV-uninfected children [121]. 
The pneumococcal conjugate vaccines have demonstrated high efficacy against radiologically-
confirmed pneumonia and IPD among HIV-infected and uninfected African children in 
randomised controlled trials conducted in SA and the Gambia using PCV9 [109;122]. In HIV-
infected children however, the antibody response was lower than in uninfected children 
[123;124]. In SA, there was at least a 65% reduction in IPD due to PCV9 in HIV-infected 
children, while in the HIV-uninfected; IPD was reduced by 83% [109]. There have been studies 
showing that utilisation of pneumococcal conjugate vaccines can help reduce the fatality and 
severity of pneumonia and IPD in HIV-infected children [125]. The burden of hospitalisation due 
to pneumococcal pneumonia in HIV-infected children was also reduced by vaccination 
[122;126]. Use of the conjugate vaccines in SA have the potential to decrease penicillin and 
multi-drug resistance amongst pneumococcal strains [78]. 
1.9 Possible post-vaccine effects 
The pneumococcus is naturally transformable and has the ability to take up foreign DNA through 
homologous recombination [127]. To escape vaccine pressure and as a survival mechanism, the 
pneumococcus can take up foreign capsular genes and express a different capsule that is not 
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targeted by the vaccine. This phenomenon is known as capsular switching and the strains are 
known as vaccine-escape recombinants [128]. The reduction in IPD and carriage due to vaccine 
serotypes have opened an ecological niche for the serotypes that were not prevalent to fill the gap 
left by the vaccine serotypes, known as serotype replacement [129]. An increase in non-PCV 
serotypes in carriage might also be due to “unmasking‟‟ of these serotypes due to eradication of 
vaccine and vaccine-related serotypes that could not be detected due to serotyping techniques 
used, as explained by Weinberger et al [130]. However, randomised, placebo- controlled clinical 
trials using PCV9 in SA [131] and the Gambia [132] evidenced that serotype replacement in 
carriage was due to acquisition of new serotypes (true serotype replacement) in vaccinated 
children. 
 
Following the introduction of PCV7 and the subsequent reduction in vaccine and vaccine-related 
serotypes, there has been an increase in non-vaccine serotypes resulting in serotype replacement 
in areas where the vaccine is routinely used. Serotype replacement has been observed in carriage 
as well as disease episodes. However, compared to the massive reduction in IPD due to vaccine 
and vaccine-related serotypes, the burden of disease caused by non-vaccine serotypes remained 
low in US, although it is statistically significant [133]. An increase in the carriage and incidence 
rates of IPD caused by non-vaccine serotypes has been observed in countries such as the US, 
France, England as well as in other countries for both vaccinated and unvaccinated populations 
[100;128;129;134]. In the United Kingdom (UK), the incidence of IPD after vaccination 
increased in individuals ≥5 years of age, and remained unchanged in children <5 years of age in 
2002-2009 due to the increase in non-PCV7 serotypes [135]. Similarly, in Spain, IPD incidence 
rates remained unchanged, due to an increase in IPD due to non-vaccine serotypes, especially in 
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the adult age groups [136-138]. However, the massive benefits offered by PCV7 on reduction of 
disease due to vaccine and vaccine-related serotypes in those settings, is still substantial [139]. 
This might be due to the fact that non-PCV serotypes are thought to be less virulent than PCV 
types.  
 
Prior to meningococcal polysaccharide conjugate vaccine roll-out in routine immunisation 
programmes, capsular switching was observed in Neisseria meningitidis showing that vaccine use 
is not the only factor contributing to capsular switching and serotype replacement [140;141]. 
However, the vaccine might be associated with increased rates of these mechanisms. Serotype 
replacement and capsular switching pose great challenges for current vaccine effectiveness and 
future vaccine development [100].  
1.9.1 Serotype 19A 
Serotype 19A is now the leading serotype in carriage, invasive and non-invasive disease in all age 
groups in the US as well as in certain other countries where PCV7 is used routinely [142-146]. 
The emergence of 19A was due to the expansion of the pre-existing clone that was circulating 
before introduction of the conjugate vaccine. However, recent evidence indicates that these 
emerging global clones are vaccine-escape recombinants [147;148]. IPD caused by serotype 19A 
increased from 2.6 to 11.1 cases per 100 000 population from 1998-1999 to 2007, for children <5 
years in the US [90]. In France in 2007, after PCV7 introduction in 2006, serotype 19A accounted 
for 63% (110/173) of cases of otitis media in children <5 years [146]. IPD due to serotype 19A 
has now stabilised in the US with only a small increase observed in adults between 50 and 64 
years [149]. The emerging non-vaccine serotype 19A is also more likely to be multidrug resistant 
[142;145;150;151]. Although the CPS structures of serotypes 19A and 19F are closely related 
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[44], serotype 19F (PCV serotype) offers little or no cross-protection against serotype 19A IPD 
[152]. The inclusion of serotype 19A in the recently licensed PCV13 might significantly reduce 
IPD and carriage due to this serotype. 
1.9.2 Serogroup 6  
Serogroup 6 serotypes are important in the epidemiology of disease-causing serotypes. There are 
four serotypes belonging to serogroup 6; namely; 6A, 6B, 6C and 6D. Serotype 6B, historically, 
was one of the leading paediatric serotypes [153]. There were only 90 serotypes described until 
2007, when a 91
st
 serotype belonging to serogroup 6, serotype 6C was discovered through a 
mouse monoclonal antibodies immunoassay [43;154]. Retrospective studies have revealed that, 
although unrecognised, this serotype had been in circulation for decades and was misidentified as 
serotype 6A, due to the serological similarities between the two serotypes. Serotypes 6A and 6B 
differ by a single nucleotide polymorphism (SNP) in the wciP gene of the capsular 
polysaccharide synthesis locus, due to a single recombinational event leading to a different 
rhamnose-ribitol linkage. However, in serotype 6C; the gene wciN is completely replaced with 
wciNβ of unknown origin, probably from a non-pneumococcal source [155], resulting in the 
replacement of galactose residues in serotype 6A by glucose residues in serotype 6C (Figure 6) 
[154;156]. Polyclonal antisera used for traditional serotyping could not distinguish between the 
two subtypes [43]. However 6C-specific antiserum has subsequently been developed [157]. 
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6A 2)-Galactose- (13) Glucose(13)- Rhamnose (13)-Ribitol-(5P 
6B 2)-Galactose- (13) Glucose(13)- Rhamnose (14)- Ribitol-(5P 
6C 2)-Glucose- (13) Glucose(13)- Rhamnose (13)- Ribitol-(5P 
6D 2)-Glucose- (13) Glucose(13)- Rhamnose (14)- Ribitol-(5P 
Figure 6. Comparison of serotypes 6A, 6B, 6C and 6D polysaccharide structures with the main 
differences between the serotypes highlighted in bold [40;43;158] 
 
In the pre-PCV7 era, the prevalence of serotype 6C was low in countries like Brazil and US 
[159;160]. Similarly, in SA between 2005 and 2006, the prevalence serotype 6C was low, 
accounting for only 5% (30/606) of isolates initially serotyped as 6A [161]. However, in 
countries with routine conjugate vaccine use, serotype 6C is the predominant serogroup 6 
serotype for both carriage and disease, due to the reduction in disease caused by serotypes 6A and 
6B [162-165]. Serotype 6B is included in PCV7 and offers cross-protection to serotype 6A [166]. 
An increase from 0.22 to 0.58 cases per 100 000 population was observed for IPD caused by 
serotype 6C alone between 1999 and 2007 in the US [167].  
 
After the discovery of serotype 6C, a new serotype 6D was proposed and constructed in vitro 
from a single homologous recombination event in the serotype 6B wciN gene, as had been found 
in serotypes 6A and 6C [168]. Serotype 6D contains the wciP from serotype 6B and wciNβ from 
serotype 6C. Subsequently, serotype 6D isolates have been recovered from the nasopharynx of 
healthy children [40;158]. In 2010-2011, carriage isolates belonging to this new serotype have 
been reported in various settings in South Korea [169], Japan [170], South America [171] and 
China [172]. In 2010, the first case of invasive disease due to serotype 6D was reported in Europe 
[173;174] 
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In 2011, genetic analysis of the biosynthetic loci of serogroup 6 serotypes revealed that serotypes 
6C and 6D did not evolve from serotype 6A and 6B respectively [175]. The genetic analysis 
showed genetic profiles that were not related to either serotype 6A or 6B for serotype 6C and 6D 
isolates studied. The cps loci of serotypes 6C and 6D are 98.6% identical. Identification of 
serogroup 6 serotypes is of importance to evaluate whether disease was a result of vaccine failure 
(serotypes 6A or 6B) and to monitor disease caused by these newly identified serotypes. Recently 
in 2011, immunological studies showed that in fact, the inclusion of serotype 6A in the 13-valent 
pneumococcal conjugate vaccine offers cross-protection to disease due to serotype 6C [176]. 
Thus, constant monitoring of IPD due to serogroup 6 serotypes is of utmost importance for 
epidemiological analysis.  
 
Other vaccine replacement serotypes that are increasing in the US are serotypes 15A, 23A, 33F, 
35B, 22F, and 7F [90;150]. As with serotype 19A, these replacement serotypes are associated 
with penicillin resistance and multi-drug resistance.  
1.9.3 Empyema  
While pneumonia hospitalisations and mortality have decreased drastically due to conjugate 
vaccine utilisation, there has been an increase in pneumonia complicated by empyema [177;178]. 
Empyema is the accumulation of pus in the normally sterile pleural cavity. The increase during 
the post-PCV7 era was observed in older children of 2-4 years [179] and was due to S. 
pneumoniae. Non-PCV7 serotypes (serotypes 1, 3, 19A and 7F) [177;180] were associated with 
this complication, suggesting that empyema might be a replacement disease caused by non-
vaccine serotypes [181;182].  
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1.10 Importance of monitoring serotypes 
Determination of serotypes is important in order to monitor the burden of disease caused by 
specific serotypes and therefore know which serotypes should be included in the conjugate 
vaccine formulations. The emergence of multidrug-resistant global clones such as 19A, other 
replacement serotypes and the discovery of new serotypes warrants continuous and efficient 
monitoring of serotypes. The inclusion of additional serotypes in the new PCV formulations e.g. 
serotype 1 and 19A in PCV13, further strengthen the ongoing need for continuous surveillance in 
order to identify any new replacement serotypes that may emerge. The discovery of a new 
subtype within an already established serotype such as 19A is also of global concern for 
determining the true burden of disease caused by this serotype. The WHO has initiated the 
Pneumococcal Global Serotype Project (GSP). One of the objectives of the project was to 
determine the distribution of invasive disease-causing serotypes and variations between regions, 
including among GAVI (Global Alliance for Vaccines and Immunisation)-eligible countries 
[183]. The project committee gave recommendations on which vaccines will be suitable for a 
specific region and which serotypes are to be included in future vaccine formulations [50;184] by 
using global serotype distribution data obtained through published and unpublished work. Over 
ten million cases and around one million deaths worldwide were caused by serotypes included in 
PCV10 and PCV13 formulations, and the committee recommended that utilisation of this vaccine 
in Africa and Asia would decrease the high burden of IPD in these areas. It is important to 
constantly monitor seroepidemiological changes in a fast, less complex and cost effective 
manner. 
. 
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1.11 Aim and Objectives 
 
The aim of this study was to establish and evaluate molecular methods for serotyping of 
Streptococcus pneumoniae from isolates and culture-negative clinical specimens.  
 
This has been achieved through the following objectives: 
I. To establish conventional and RT-PCR assays for serotyping of S. pneumoniae using 
pneumococci of known serotypes.  
II. To determine the utility of conventional PCR in determining pneumococcal serotypes 
from culture-positive samples. 
III. To determine the utility of conventional PCR in determining pneumococcal serotypes 
from culture-negative samples positive for pneumococci by lytA PCR. 
IV. To determine the utility of RT-PCR assays for serotype determination directly from 
culture-negative samples positive for pneumococci by lytA PCR.  
V. To determine the serotype distribution in culture-negative samples received as part of 
SARI and empyema studies.  
VI. To compare the distribution of serotypes between culture-positive and culture-negative 
samples. 
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2 Materials and Methods 
2.1 National surveillance 
The Centre for Respiratory Diseases and Meningitis (CRDM) of the National Institute for 
Communicable Diseases (NICD), a division of the National Health Laboratory Service (NHLS), 
houses the national reference laboratory for IPD in SA. CRDM conducts laboratory-based 
nationwide surveillance of IPD. The case definition for IPD is the isolation or identification of S. 
pneumoniae from a normally sterile site (e.g. pleural fluid, blood, joint and cerebrospinal fluid 
(CSF)) by either a positive culture, lytA detection by PCR or positive latex antigen test with a 
matched Gram stain result. Demographic information and patient details of all cases are stored in 
the national pneumococcal database for each year of surveillance. IPD cases identified through 
the NHLS laboratory electronic database but with no isolate submitted to the NICD laboratory are 
still recorded on the national surveillance database. Approximately 126 NHLS regional 
laboratories and private laboratories across the nine provinces of SA participate in the national 
surveillance through a GERMS-SA surveillance network (Group for Enteric, Respiratory and 
Meningeal Disease Surveillance in South Africa) [82].  
 
The laboratories submit pneumococcal isolates to CRDM on Dorset egg transport media.  Some 
specimens with latex positive and /or Gram stain positive for pneumococci do not yield a positive 
bacterial growth, and for these cases, the clinical specimens are sent to CRDM for further 
confirmation of IPD by PCR. Clinical diagnostic specimens without a Gram stain or latex 
agglutination results from patients with a clinical suspicion of meningitis or septicaemia are also 
sent to CRDM for urgent detection of pneumococcal DNA by PCR. 
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2.2 Viable isolates 
2.2.1 Source of bacterial cultures 
Upon receipt at CRDM, isolates (i.e. culture-positive) from the transport medium were sub-
cultured onto 5% horse blood Columbia base agar plates (Oxoid, Hampshire, UK) using a sterile 
loop. Optochin discs (Mastdisk, Merseyside, UK), were used for identification of S. pneumoniae. 
Optochin (ethyl hydrocuprein) is a chemical agent used for basic screening of pneumococci. The 
majority of pneumococcal isolates are susceptible to optochin, forming a zone clearance around 
the discs of ≥11mm, with few exceptions. The blood agar plates were incubated at 37ºC in 5% 
CO2 for 18-24 hours. Heavy pure growths of S. pneumoniae were stored in 10% skim milk 
(Oxoid) and stored at -70ºC for further analysis. Optochin-resistant isolates, which were 
identified as pneumococcus by colony morphology, bile solubility and Gram stain, were 
confirmed by a positive lytA RT-PCR. 
 
Contaminated cultures were sub-cultured on selective media, namely, 5% blood agar plates 
supplemented with 5 µg/ml gentamycin (Oxoid) to obtain pure growth of the pneumococcus. The 
pure colonies were sub-cultured on 5% blood plates for heavy growth and stored as previously 
described. Contaminated cultures from which pneumococcus could not be isolated, were treated 
as non-viable transport medium samples described below in section 2.3.1.  
 
2.2.2 The Quellung reaction 
All pneumococcal isolates were serotyped at CRDM by the Quellung reaction using type-specific 
antisera (Staten‟s Serum Institute, Copenhagen, Denmark). The process involved preparing a 
light suspension of approximately 0.5 McFarland standards by picking not more than five 
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colonies of the pneumococcus from the 5% blood agar plates and suspending in 1 ml saline 
solution. Two smears were fixed on the glass slide by air drying. The antiserum to be tested was 
mixed with ethylene blue on a cover slip and the smears were covered with the cover slip. The 
slides were viewed on a phase-contrast microscope (Nikon, Melville, USA and Olympus, Centre 
Valley, PA, USA) to detect swelling of the capsule surrounding the cell wall.  
2.2.3 Crude extraction 
DNA extraction from pneumococcal cultures was performed using a boiling method. A small 
loopful of the culture was suspended in 200 µl sterile distilled water (sdH20) in 0.5 ml tubes 
(Thermo Scientific, Leicestershire,, UK). The pneumococcal suspensions were boiled at 95˚C for 
10 min, which bursts open the cell wall and releases the DNA. Suspensions were briefly 
centrifuged using an Eppendorf Minispin centrifuge (Merck, Whitehouse Station, NJ, USA) at 
12000 RPM to pellet the debris. The supernatant was stored at -20˚C until use.  
 
In addition to isolates, CRDM receives culture-negative specimens for confirmation of 
pneumococcal DNA. 
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2.3 Non-viable samples  
2.3.1  Types of non-viable samples 
2.3.1.1 Non-viable transport medium samples  
The regional laboratory inoculates the pneumococcus on the Dorset egg transport medium; 
however, upon receipt at the CRDM, for some, pneumococcal growth was not obtained on 5% 
blood agar plates. Pneumococcal growth was not detected from the transport medium due to three 
possible reasons: 
I. Incorrect inoculation techniques from the regional laboratory (e.g., not enough organism 
inoculated, failing to incubate after inoculation or problems with transport media used) or 
II. The organism losing viability in transit before reaching CRDM, due to its fastidious 
nature, or 
III. Contamination by another organism that outgrows the pneumococcus.  
The following methods were performed to attempt to recover the organism, 
I. Sub-culturing on a selective medium (5% blood agar with gentamycin) and incubating at 
37°C 5%, CO2 for longer periods i.e. 48 hours.  
II. Adding a nutritious liquid medium, such as BHI (Brain Heart Infusion Broth, Oxoid) and 
incubating at a 5% CO2 and 37˚C for 2 hours to enhance the growth of the organism. 
These specimens were classified as culture positive at the regional laboratory, but non-viable on 
receipt at CRDM. 299 NVTMs from year 2010 were available for this study.  
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2.3.1.2 Clinical diagnostic specimens 
Diagnostic specimens for urgent PCR detection of DNA of the three common pathogens causing 
meningitis i.e. S. pneumoniae, N. meningitidis and Haemophilus influenzae were sent to the 
CRDM. This is a routine urgent diagnostic assay offered by CRDM since 2005. The clinical 
specimens used in this study were from normally sterile sites e.g. blood, CSFs, and pleural fluids, 
with a suspicion of IPD. The specimens were culture negative possibly due to  
I. Patients receiving antibiotic therapy before collecting the specimen in the health-care 
facility.  
II. Delays in processing of specimens resulting in non-viability of organism.  
III. Specimens kept at unfavourable conditions before being processed or sent to CRDM.  
For this study, CSFs (n=40), blood specimens (n=10) and a pleural fluid (n=1) received in 2010 
were used. 
2.3.1.3 Beep-positive, subculture-negative blood cultures 
Culture-negative, beep-positive blood culture bottles, mainly from Chris Hani Baragwanath 
Hospital, are routinely received by CRDM. These blood cultures were identified by the 
BacT/ALERT
®
 system as positive for microbial growth at the regional laboratories. The system is 
rapid and fully automated and is used to detect growth from blood specimens inoculated into vials 
containing media. Microbial growth is detected by a sensor, which senses the accumulation of 
carbon dioxide (C02) in 5-10min intervals. The accumulation of C02 or consumption of oxygen 
(02) is indicative of microbial metabolism of the media. A “beep-positive” reading indicates the 
presence of viable microorganism in the vial. For identification, Gram stain and additional 
microbial identification tests are performed. Presence of the pneumococcus is confirmed in these 
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specimens by latex agglutination, Gram stain or pneumococcal antigen test such as Binax NOW® 
[185;186] but no bacterial growth is observed on subculture culture possibly due to: 
I. Autolysis of the pneumococcus facilitated by autolysin enzymes present in all 
pneumococci due to delays in removing the bottles from the automated system.  
At our reference laboratory, such samples undergo routine qualitative lytA RT-PCR testing to 
confirm pneumococcal identification. In 2010, 154 beep-positive, subculture-negative blood 
culture bottles were received.  
2.3.1.4 Severe Acute Respiratory Illness (SARI) blood specimens 
The SARI surveillance study was established in February 2009 at six hospitals in four provinces 
of SA, namely, Gauteng (Chris Hani Baragwanath hospital), KwaZulu-Natal (Edendale hospital), 
Limpopo (Mapulaneng and Matikwana hospitals) and North-West (Klerksdorp and Tshepong 
hospitals). The aim of the SARI surveillance study was to describe the aetiology of severe 
pneumonia in SA as well as identify risk factors associated with severe pneumonia. CRDM 
collects whole blood samples for the quantitative detection of the pneumococcus in order to 
estimate the prevalence of pneumococcal pneumonia in these patients. Whole blood specimens, 
from patients meeting the SARI case definition, were collected in EDTA tubes within 24 hours of 
admission to the hospitals and sent to CRDM for pneumococcal detection using quantitative lytA 
RT-PCR. Vaccination status was obtained from vaccination cards on admission. PCV7 eligible 
were defined as all children <5 years and born after 15/02/2009 or 3 weeks old by the time of 
vaccine introduction. Children ≥6 weeks and <2 years were regarded as vaccinated if they had 
received at least 1 dose of PCV7 at least 14 days before symptoms onset. This was considered 
sufficient period for the vaccine to have elicited an immune response. 372 of lytA-positive 
specimens from 2009-2010 were used for this study.  
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2.3.1.5 Pleural fluids collected in an empyema study 
CRDM collaborated with medical specialists from Red Cross Children‟s Hospital (RCCH), Cape 
Town, SA. The study involved management of pleural empyema with new treatment modalities: 
fibrinolysis and video-assisted thoracoscopic surgery (VATS) in comparison with the traditional 
antibiotic treatment (with or without chest drain insertions) for management of this disease. The 
aim of the study was to determine the aetiological agent and outcome of empyema cases, from 
children admitted and treated with new methods in comparison with historical controls who never 
received the new treatment modalities. CRDM detected the presence of pneumococcal DNA in 
pleural tap specimens using a qualitative RT-PCR assay, which simultaneously detects the 
presence of S. pneumoniae, H. influenzae and N. meningitidis. By the end of 2010, 19 lytA-
positive pleural fluids for this study were available for molecular serotyping.  
2.3.2 DNA extraction from culture-negative samples 
For clinical specimens, NVTMs and stored isolates that had lost viability during storage, an 
automated DNA extraction was performed. The MagNA Pure instruments (Roche, Forrenstrasse, 
Switzerland) extract DNA using magnetic bead technology. The process involves binding of 
DNA molecules to the magnetic bead particles. After washing of unbound DNA molecules, the 
bound DNA is then eluted into an elution buffer by magnetic force and the beads are retained. 
The MagNA Pure LC 2.0 instrument (processing up to 32 samples per run) and MagNA Pure LC 
DNA Isolation Kit III were used for the extraction of DNA from SARI blood specimens. The 
MagNA Pure Compact (processing up to 8 samples per run) and MagNA Pure Compact Isolation 
Kit I (Roche diagnostics, Indianapolis, USA) were used to extract DNA from all clinical 
specimens and non-viable transport medium samples. DNA extraction was performed according 
to the manufacturer‟s instructions from either 200 μl or 100 µl of sample, depending on the 
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volume of sample available. The DNA was eluted into a 100 µl (for 200 µl extraction volume) or 
50 µl (for 100 µl extraction volume) of elution buffer and stored at -20°C until further use.  
2.3.3 Molecular detection of pneumococcus from culture-negative samples 
2.3.3.1 lytA real-time PCR 
The lytA RT-PCR was performed on the following samples: beep-positive, subculture-negative 
blood cultures, NVTMs and SARI blood specimens to confirm the presence of pneumococcal 
DNA. Primers and a FAM-labelled TaqMan minor groove-binding (MGB) probe, (Applied 
Biosystems, Warrington, UK) were used in the assay at a final concentration of 200 nM. Each 25 
µl reaction consisted of 2X TaqMan gene expression mastermix (12.5 µl) (Applied Biosystems), 
2.5 µl of DNA, primer pair and probe to the above-mentioned concentrations and sterile distilled 
water. The primers and probe sequences were; Forward primer (F373) 5‟-
acgcaatctagcagatgaagca-3‟, Reverse primer (R424) 5‟-tcgtgcgttttaattccagct-3‟, Probe (Pb400) 5‟-
tgccgaaaacgcttgatacagggag-3‟-FAM [28].  
2.3.3.2 HNS real-time PCR 
A multiplex RT-PCR assay [187] for the simultaneous detection of H. influenzae (hpd; protein 
D), N. meningitidis (ctrA) and S. pneumoniae (lytA) (HNS) is a routine diagnostic assay 
performed at CRDM since 2005. The assay was carried out on all routine diagnostic clinical 
specimens and pleural fluids for the empyema study. Primers and black hole quencher (BHQs) 
probes were obtained from the CDC. Each 25 µl reaction consisted of 12.5 µl Invitrogen 
Platinum PCR super-UDG master mix (Invitrogen, Carlsbad, CA, USA), 2 µl of DNA, primer 
pairs and probes to the final concentration as listed in Table 10 (appendix D), and sdH20 to make 
up the volume. 
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2.3.4 PCR conditions and interpretation of results 
The 7500 Fast real-time PCR instrument (Applied Biosystems) was used. All reactions were 
carried out in 0.1 ml 96-well reaction plates (Applied Biosystems). Universal cycling conditions 
were used for both the HNS and lytA real-time assays i.e. Stage 1: 50˚C for 2 min; Stage 2: 95˚C 
for 10 min and Stage 3: 40 cycles of two-staged temperature profile of 95˚C for 15 sec and 60˚C 
for 1 min. The increase in fluorescent signal of the sample beyond the threshold was recorded as 
a positive result for the presence of the pneumococcal lytA gene. The cycle threshold (Ct-value) 
value at which the fluorescence crossed the threshold was recorded. If no increase in fluorescent 
signal above the threshold was observed within 40 cycles for lytA, the sample was reported as 
negative for the pneumococcus. For the HNS assay, the results were considered positive if the Ct-
value was <35 and negative if there was no increase in fluorescent signal beyond the threshold 
within 40 cycles of amplification. For the results with lytA Ct-values of ≥35 but ≤40 on HNS, an 
accompanying latex agglutination positive result for pneumococcus, Gram-positive diplococci, or 
other clinical information such as septicaemia were needed to confirm the presence of 
pneumococcus as the disease-causative agent. For the quantitative lytA RT-PCR, the threshold 
was set at 0.05 for all analysis, and results were interpreted as being positive if there was an 
increase in the fluorescence signal beyond the set threshold within 40 cycles. The DNA copies 
extrapolated from the standard curve were halved, accounting for the 200 µl sample extraction 
volume in 100 µl elution volume. 
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2.4 Establishment of conventional PCR serotyping assay 
2.4.1  Selection of isolates for setting up of conventional PCR serotyping assay  
Bacterial cultures (n=96) were randomly (www.random.org) selected by serotype from the 2007 
surveillance isolates. These isolates were previously serotyped using the Quellung reaction. These 
isolates represented three isolates each of 32 of 33 serogroups/types detected by C-PCR assay. A 
serotype 2 control, to make up for the 33 serotypes, was not available amongst the surveillance 
isolates (2003-2010). Furthermore, isolates representing seven different serotypes (n=21) not 
detected by the assay but common in SA were selected to confirm the specificity of the assay.  
2.4.2 Selection of isolates for determining the utility of conventional PCR serotyping assay 
Following setting up of the assay, approximately 12% of isolates were randomly selected 
(www.random.org/sequences) from the surveillance isolates collected from January 2008 through 
December 2009 (410/3327 for 2008 and 419/3391 for 2009). All isolates had previously been 
serotyped using the Quellung reaction. The isolates were retrieved from storage in -70°C as 
described in section 2.2 and sub-cultured on blood agar plates (Oxoid) overnight. DNA was 
extracted by the boiling method as described in section 2.2.3. A total of 27 and 49 isolates from 
2008 and 2009 respectively, were no longer viable after retrieval from -70°C and therefore DNA 
was extracted directly from the storage medium i.e. skim milk by automated DNA extraction as 
described in section 2.3.2  
 
2.4.3 Serotyping assay 
Primer pairs are listed in Table 11 (appendix E) The method was adapted from that developed by 
the Streptococcus Laboratory of the CDC in Atlanta, USA [68]. Primer concentrations and 
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reagent compositions for each reaction are shown in Table 12 (a-f, appendix E). The serotypes 
were grouped to allow >50 bp differences between serotypes for greater resolution on an agarose 
gel. The final volume of the PCR was 25 µl using 2 µl of DNA template.  
PCR reactions were tested and compared using two methods: 
2.4.3.1 Amplitaq Gold DNA polymerase 
Reactions were performed using AmpliTaq® Gold DNA polymerase supplied with GeneAMP 
10X PCR Buffer and MgCl2 (Applied Biosystems) using 2.5 units of enzyme per reaction. The 
final concentration of deoxynucleotide triphosphate (dNTPs) and MgCl2 were 200 µM and 3.5 
nM respectively, in a 25 µl reaction. The PCR reactions were carried out in a 2720 Thermal 
Cycler (Applied Biosystems) using either 0.2 ml thermo–tubes (Thermo Scientific) or 96-well 
microplates (Axygen Scientific, California, USA).  
2.4.3.2 Qiagen Multiplex PCR Mastermix 
Reactions were performed using the Qiagen mastermix (containing HotStart DNA polymerase, 
multiplex PCR buffer with MgCl2 and dNTP mix) (Qiagen, Hilden, Germany).  
 
Cycling conditions included an activation step at 95˚C for 10 min, followed by 35 cycles of 94˚C 
for 30 sec, 54˚C (59˚C for reaction 4, 5 and 6 when using Amplitaq Gold DNA Polymerase) and 
a final holding step at 72˚C for 10 min.  
2.4.4 Agarose gel electrophoresis 
A volume of 10 µl of 2.5% Bromophenol blue solution (Sigma-Aldrich, St Louis, MO USA); 
loading dye was added to the 25 µl of PCR product. 10 µl of the mixture (PCR product + loading 
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dye) was loaded on a 2% Seakem LE Agarose gel (Whitehead Scientific, Rockland, USA) 
containing 10 mg/ml ethidium bromide (Sigma-Aldrich) and electrophoresis was performed in 
1X TAE buffer Tris (Sigma-Aldrich and Merck)-Acetate (Merck) –EDTA (Merck) at 100 V 
(voltage) for 1h30 min. The gels were visualised using ultraviolet light. A Molecular Imager® 
Gel Doc
TM
 XR System (Bio-Rad Laboratories, Hercules, California, USA) was used to visualise 
and capture the agarose gel images. 
The serotypes of the control isolates were assigned based on band sizes using a 100 base pair 
(100 bp-1000 bp) HyperLadder IV molecular weight marker (Bioline, Humber Road London, 
UK). The assigned serotype was then compared with the serotype obtained using the Quellung 
reaction. Subsequently, serotypes for 2008 and 2009 isolates and non-viable samples were 
determined by comparing the sizes of products to that of 2007 isolates controls and the molecular 
weight marker. 
2.5 Establishment of real-time PCR serotyping assay 
2.5.1  Selection of isolates for setting up of real-time PCR serotyping assay  
For RT-PCR, only isolates representing 22 serogroups/types selected were used from 2007 
(n=69) isolates used for validation of C-PCR. Serogroup 15 was represented by 3 isolates of 
serotype 15A and serotype 15B/C each, i.e. serogroup 15 was validated by 6 isolates in total.  
2.5.2 Selection of isolates for determining the utility of real-time PCR serotyping assay 
To determine the specificity of the RT-PCR serotyping assay, 228 isolates from 2008 surveillance 
were selected. These isolates were a representation of all 65 serotypes/groups identified by the 
Quellung reaction in SA for 2008. We aimed to have each serotype represented by four different 
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isolates. 2008 was used as a reference year, and where four isolates for a specific serotype could 
not be obtained from 2008 surveillance, isolates from 2009 surveillance were selected to 
complete the total representation of four isolates per serotype. Where four isolates per serotype 
could not be obtained from the two years, the total available for the two years was used for that 
serotype. All four isolates could be obtained for 51 serotypes/groups. Serotypes which had 1-3 
isolates due to total number of samples received or culture no longer available for the study years 
combined were serotypes 27 (1), 29 (3), 42 (1), 43 (1), 10B (1), 12B (3), 17A (1), 19B (3),28 (2), 
28A (2), 33B (2), 35A (1), 33A (3) and 9L (1). All isolates were retrieved from storage at -70˚C 
and sub-cultured overnight on 5% horse blood agar plates and DNA was extracted using the 
automated extraction method directly from skim milk as described in 2.3.2.  
2.5.3 Serotyping assay  
The assay used in this study was adapted from Azzari et al [34]. The RT-PCR serotyping assay 
consisted of 21 singleplex reactions initially, later validated to 11 duplex reactions with an 
additional primers/probe set for serotype 6C/D (Table 13 & 14, appendix F). The primer pairs 
targeted 11 specific serotypes (serotypes 1, 3, 4, 5, 8, 14, 20, 19A, 23F, 35B and 38) and 11 
serogroups (serogroup 6, 6C/D 7A/F, 9A/V, 10A/B, 12A/B/F, 15, 18B/C, 19B/F, 22A/F and 
33A/F). Primer pair sequences for serogroups 22A/F and 6C/D were obtained from the CDC. 
Fluorescent MGB probes (Applied Biosystems) were labelled with either FAM or VIC dye. For 
FAM-labelled probes, the final concentration for both primers and probes was 200 nM whereas 
for VIC-labelled probes, both probe and the corresponding primers were used at a final 
concentration of 400 nM.  
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All reactions were carried out to a final volume of 25 µl consisting of 12.5 µl 2X TaqMan gene 
expression mastermix (Applied Biosystems), 2.5 µl of DNA, primer pair and probe to the above-
mentioned concentrations for each serotype and sterile distilled water (sdH2O) to make up the 
volume. MicroAmp Fast 96-well reaction plates (0.1 ml) were used with a 7500 Fast real-time 
PCR instrument (Applied Biosystems). A no template control (NTC) was included in all reactions 
as well as the 10X and 100X dilutions of the controls. The universal cycling conditions, as 
described were used. Results were interpreted as being negative if no significant increase in 
fluorescent signal of the sample beyond the threshold was observed within 40 cycles, as 
previously described.  
 
It was hypothesised that the lytA Ct-value and the corresponding serotype Ct-value would not 
differ significantly from each other. All lytA-positive samples were assumed to contain sufficient 
DNA for a serotype to be detected by RT-PCR. A sample yielding lytA positive but serotype-
negative results was therefore assumed to be of a serotype/group not detected by any of the 
serotyping assays. In cases where two serotypes were detected, the serotype with the lower Ct-
value (and/or closest to the lytA Ct-value) was reported as the disease-causing serotype. A sample 
was reported as having mixed serotypes if the two serotypes detected were within a range of ±3 
Ct-values.  
2.6 Establishment of serogroup 6 differentiation assays  
2.6.1 Selection of isolates for serogroup 6 differentiation by conventional and real-time 
PCR assays 
Isolates representing serotypes 6A (n=5), 6B (n=5) and 6C (n=5) were randomly selected from 
2007 surveillance isolates. Isolates from 2008 (n=62) and 2009 (n=49) were used to further 
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validate the utility of serogroup 6 differentiation PCR reactions. In addition, 178 isolates from 
2010 surveillance isolates that had been serotyped as serotype 6B (n=167) and 6C (n=11) by the 
Quellung reaction were selected for further validation and to screen for serotype 6D. DNA from 
178 isolates received in 2010 was extracted directly from skim milk using an automated 
extraction technique.  
2.6.2 Serogroup 6 differentiation assays 
Serogroup 6 differentiation was performed using two PCR assays:  
2.6.2.1 The conventional PCR assay 
An internal control for confirmation of serogroup 6 that was used in reaction 1 of the C-PCR 
assay was included in all reactions at a final concentration of 300 nM (product size of 250 bp) 
[68]. The primers used for serogroup 6 differentiation are listed in Table 15 (appendix G). 
Initially, the assay consisted of two duplex reactions (Table 16 b & c, appendix G). The first 
reaction was aimed to target the wciP gene of serotype 6B with a product size of 155 bp. The 
second reaction targets wciNbeta, which amplifies serotype 6C with a product size of 359 bp 
(wciNβS1 and wciNA2, outer primer set) or 308 bp (wciNβS2 and wciNA1, inner primer set) but 
does not amplify serotype 6A‟s. All isolates that were negative in reaction 2 were assigned 
serotype 6A. All isolates identified as serotypes 6B from reaction 1 and were positive for the 6C 
primers in reaction 2, were assigned a serotype 6D.  
To limit the number of conventional PCR reactions, the two reactions were combined to a single 
reaction to differentiate all serogroup 6 serotypes using one multiplex reaction (Table 16a, 
appendix G). If the internal control band size (250 bp), and both the band for serotype 6B (155 
bp) and 6C (309/359 bp) were observed, then the sample was assigned a novel serotype 6D. PCR 
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products were run on a 2% agarose gel for 1h30min as described in section 2.4.4. For 2007, 2008 
and 2009 isolates, both the two duplex reactions and the multiplex reaction were performed, 
while for 2010 serogroup 6 isolates, only the multiplex reaction was performed.  
 
The final primer concentrations were 500 nM and 700 nM for wciP (6B) and wciNbeta (6C and 
6D), respectively. All reactions were performed in a final volume of 25 µl, consisting of 12.5 µl 
of 2X Qiagen mastermix (Qiagen), primers pairs to the above-mentioned concentration, 2 µl of 
crude DNA extract and sdH2O to make up the volume. The PCR reactions were carried out in a 
2720 Thermal Cycler (Applied Biosystems) using either 0.2 ml thermo–tubes (Thermo Scientific) 
or 96-well microplates (Axygen Scientific). The cycling conditions were 95˚C for 10 min, 35 
cycles of 94˚C for 30 sec, 62˚C for 60 sec, and 72˚C for 60 sec. The final holding temperature 
was 72˚C for 10 min and storage at 4˚C.  
2.6.2.2 The real-time PCR assay  
The primer sequences distinguished serotype 6C/6D from serogroup 6. The assay was duplexed 
with serogroup 6 primers. Primers and VIC-labelled probes were used at a concentration of 400 
nM for serogroup 6, and 200 nM final concentrations were used for primers and FAM-labelled 
probes for serotype 6C/6D. All reactions and cycling conditions were carried out as described in 
2.3.4 for the RT-PCR serotyping assay validation. 
Results were interpreted as positive for serotype 6C/6D if an increase in florescent signal was 
observed within 40 cycles beyond the threshold level in both serogroup 6 primers and serogroup 
6C/6D set. If an increase in fluorescent signal was observed before the end of the 40
th
 cycle for 
serogroup 6 primer set, but no fluorescent signal increase for serotype 6C/6D, the results were 
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interpreted as being positive for serotype 6A/6B. If no increase in fluorescent signal was observed 
for both primers/probe sets, then the sample was presumed not to belong to serogroup 6. 
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Table 1. Summary of samples used in this study 
 
Year Sample type 
Number of 
samples 
Number of viable 
cultures 
Serotyping PCR assay 
2007 Stored cultures 132 132 C-PCR
a 
and RT-PCR
b
 
2008 Stored cultures 411 384
c
 C-PCR 
2008-2009 Stored cultures 228 Not sub-cultured
d
 RT PCR 
2009 Stored cultures 419 370
e
 C-PCR 
2009-10 Empyema pleural fluids 19 -* RT-PCR 
2009 SARI specimens 151 -* RT-PCR 
2010 Stored cultures 178 Not sub-cultured
d
 Serogroup 6 differentiation 
2010 SARI specimens 219 -* RT-PCR 
2010 Blood cultures 154 16** C-PCR and RT-PCR 
2010 Cerebrospinal fluids 40 5** C-PCR and RT-PCR 
2010 Blood and pleural fluids 11 6** C-PCR and RT-PCR 
2010 Non-viable transport medium samples 299 66** C-PCR and RT-PCR 
a 
C-PCR–conventional PCR, b RT-PCR–real-time PCR, c27 cultures lost viability on skim milk storage, d not sub-cultured on blood agar plates, DNA extracted 
directly from skim milk, 
e
49 cultures lost viability on skim milk storage 
*no culture available, ** Viable isolates retrospectively received.
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2.7 Statistical Analysis 
Serotyping results for C-PCR and RT-PCR were entered onto a Microsoft Excel database 
(Microsoft Office professional edition 2003, Microsoft Corporation). For cultures, where 
Quellung reaction serotypes were available, phenotypic serotypes were used for comparative 
purposes. Sensitivity and specificity were described as the proportion of true positives and 
proportion of true negatives, respectively for primers and primers/probe sets. The sensitivity and 
specificity of the C-PCR assays were calculated using 2008 (411) and 2009 (419) isolates For 
RT-PCR, sensitivity and specificity were calculated using isolates from 2008 and 2009 (n=228). 
The sensitivity and specificity of each assay was calculated as follows: 
Sensitivity = number of true positives / (number of true positive + false positives). 
Specificity = number of true negatives / (number of true negatives + false positives). 
 
Epi Info software version 6 (CDC, Atlanta, GA, USA) was used for all statistical analysis. The 
Mantel-Haenzel chi-squared test was used to estimate if there was a difference in serotype yield 
using C-PCR or RT-PCR assays on isolates. The test was also used to compare the sensitivities of 
C-PCR and RT-PCR on culture-negative samples with low and high bacterial loads. In addition, 
the test was used to test for significant difference in serotype distribution between viable and non-
viable samples. The student‟s t-test was used to determine if there was significant loss in 
sensitivity between the singleplex and the duplex reactions of the RT-PCR serotyping assay. For 
all statistical analysis, p<0.05 was regarded as statistically significant. Analysis of data for the 
SARI surveillance programme was performed using STATA version 11.0 (StataCorp, Texas, 
USA). The Fisher‟s exact test and Pearson‟s chi-squared test were used to analyse trend in lytA 
positivity and PCV7 serotype distribution 
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2.8 Ethics 
Ethics approval for national surveillance (Protocol no.M08117) and ethics clearance for this 
project (Protocol no. M10364, Appendix H), were obtained from the Human Research Ethics 
Committee (Medical) at the University of Witwatersrand, Johannesburg, SA.  
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3 Results 
3.1 National IPD surveillance in SA 
Using all 2008 (n=3327) and 2009 (n=3391) surveillance serotyping data (by Quellung reaction), 
it was estimated that the C-PCR assay would have assigned a serotype to at least 96% of all 
isolates (i.e. culture-positive) received for each year (Tables 2 & 3). The RT-PCR assay would 
have assigned a serotype to 91% (3045/3327) in 2008 and 90% (3061/3391) in 2009. It was 
estimated that more serotypes would be assigned to isolates using C-PCR compared to RT-PCR 
serotyping assay [6460/6718 (96%) for C-PCR vs. 6106/6718 (91%) for RT-PCR, p<0.001] for 
the two years combined.  
 
Overall, 4201 cases were reported in SA in 2010. Of these, 68% (n=2859) were culture positive 
(isolates), and were serotyped using the Quellung reaction. For 93 lytA-positive culture-negative 
samples received initially, viable cultures were received at a later stage and hence were included 
in culture-positive mentioned above. Overall, culture-negative samples accounted for 10% 
(n=440) of cases and of these, 6% (26/440) were NVTMs presumably inoculated with 
pneumococcus at the regional laboratories but negative for pneumococcal DNA at CRDM by 
lytA real-time PCR assay. In addition, 22% (n=902) were cases identified retrospectively on 
audits of the participating laboratories (Figure 7). – 
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Table 2. Expected serotype coverage of the surveillance isolates using conventional PCR 
serotyping assay for 2008, South Africa  
 
Reactions Serotypes 
No. detected 
(N=3327) 
Percentage 
(%) 
Reaction 1 14,6A/B/C,23F,19A,9V 1507 45.3 
Reaction 2 19F,3,15B/C,18,10A,7A/F 506 15.2 
Reaction 3 1,5,11A/D,9N/L,17F 534 16.0 
Reaction 4 7C/(7B/40),12F(12A/44/46),4,38/25,23A 350 10.5 
Reaction 5 8,2,34,20,22A/F,31 194 5.8 
Reaction 6 33F/(33A/37),15A,35F/47,35B,16F 121 3.6 
Total detected 33 serogroups/types 3212 96.4 
Total not detected Multiple serotypes 115 3.6 
 
 
 
Table 3. Expected serotype coverage of the surveillance isolates using conventional PCR 
serotyping assay for 2009, South Africa  
 
Reactions Serotypes 
No. detected 
(N=3391) 
Percentage 
(%) 
Reaction 1 14,6A/B/C,23F,19A,9V 1471 43.4 
Reaction 2 19F,3,15B/C,18,10A,7A/F 490 14.5 
Reaction 3 1,5,11A/D,9N/L,17F 631 18. 6 
Reaction 4 7C/(7B/40),12F(12A/44/46),4,38/25,23A 374 11.0 
Reaction 5 8,2,34,20,22A/F,31 190 5.6 
Reaction 6 33F/(33A/37),15A,35F/47,35B,16F 105 3.0 
Total detected 33 serogroups/types 3261 96.2 
Total not detected Multiple serotypes 130 3.8 
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Figure 7. Summary of national invasive pneumococcal disease surveillance for isolates and culture-negative samples received in South 
Africa, 2010. 19 culture-negative samples were not available for PCR-based serotyping assays. 
a 
299 non-viable transport medium 
samples (NVTMs) initially received, 66 received cultures at a later stage; 
b 
specimens included blood cultures, CSFs, blood and pleural 
fluids sent and only lytA positive clinical specimens were recorded as a case. 
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3.2 Validation of conventional sequential multiplex PCR 
3.2.1 Setting up of the assays using 2007 isolates 
A total of 96 isolates selected for validation of the C-PCR were in complete concordance with the 
Quellung reaction results. All the serotypes detected matched the expected band size in 
comparison with the molecular weight marker (100 bp-1000 bp) (Figure 8). No serotypes were 
assigned to the 21 isolates selected for specificity determination. Thus, the primers accurately 
detected the serotypes which the assay was designed to detect. 
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Reaction 4 
 
Reaction 5 
 
Reaction 6 
 
Figure 8. Ethidium bromide stains of an agarose gel under ultraviolet light representing the PCR 
products detected by six sequential reactions of the conventional PCR assay performed on 
isolates of known serotypes and used as controls for subsequent reactions (shown in green) in 
triplicate. All gels are flanked by a 100 bp (100 bp-1000 bp) molecular weight marker.  
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3.2.2 Determining the utility of the conventional serotyping assay using 2008 and 2009 
isolates 
The randomly selected isolates represented the majority of serotypes received in 2008 and 2009. 
All results for 2008 (n=411) and 2009 (n=419) were in concordance with the Quellung reaction 
results for serotypes included in the assay (Table 4). In some instances where the Quellung 
reaction had serotyped an isolate to factor sera, the C-PCR assay could only detect the serogroup, 
as there were no primers to detect to a specific serotype. Table 4 shows the Quellung reaction 
results, and the serotype detected by the C-PCR assay for 2008 and 2009 surveillance isolates.  
 
In 2008, there was no factor serum for serogroup 16 at CRDM, while the C-PCR primers were 
specific for serotype 16F. The C-PCR assay assigned all randomly selected 2008 serogroup 16 
isolates as serotype 16F. However in 2009, the factor serum for serotype 16F was available, and 
confirmed that the C-PCR assay had identified the isolates with the correct serotype for both 2008 
and 2009 isolates.  
 
PCR results (serotypes 4 and 19F) of two pneumococcal strains from 2008 were initially 
discrepant to the Quellung reaction results which were 9V and 23F, respectively. The Quellung 
reaction was repeated on the two discrepant cultures and both were found to contain a mixture of 
2 serotypes: 4/9V and 19F/23F. The mixtures were not observed on the initial Quellung reaction 
performed. The C-PCR confirmed the presence of the other serotype upon repeat.  
A total of 27 samples and 49 samples from 2008 and 2009, respectively from the stored skim 
milk vials did not yield growth upon retrieval. The serotype results obtained from DNA extracts 
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directly from skim milk were in concordance with the Quellung reaction results originally 
obtained from the cultures, which had subsequently lost viability.  
 
A total of 97% (397/411) from 2008 and 96% (404/419) from 2009 surveillance isolates could be 
assigned a serotype using the six sequential multiplex reactions. The majority of serotypes were 
detected within the first three reactions of the C-PCR assay. By the end of reaction 3, >75% of 
isolates for 2008 (314/411) and 2009 (315/419) had been assigned a serotype (Figures 9 & 10).  
 
The remaining 3.4% (14/411) and 3.6% (n=15/419) from 2008 and 2009 respectively, for which 
serotypes could not be assigned using the assay were serotypes that were not included in the 
assay. The actual serotypes as detected by the Quellung reaction are listed in table 4, but for the 
C-PCR assay, these samples were recorded as negative for the serotypes tested.  
 
The C-PCR assay was 100% sensitive (801/801) and specific (29/29) using 2008 and 2009 
isolates.  
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Table 4. Serotyping results and percentage coverage of each serotype obtained by Quellung reaction and conventional PCR from 
randomly selected invasive pneumococcal isolates from 2008 and 2009, South Africa.  
2008 2009 
Serotypes Isolates detected by  
Quellung reaction n (%) 
Isolates detected by 
C-PCR n (%) 
Isolates detected by 
Quellung reaction n (%) 
Isolates detected by  
C-PCR n (%) 
1 390 (12) 46 (11) 475 (14) 52 (12) 
3 108 (3) 11 (3) 112 (3) 19 (4) 
4 194 (6) 18.(4) 179 (5) 21 (5) 
5 40 (1) 4.(1) 53 (2) 5 (1) 
6A 260 (8) 28.(7) 272 (8) 31 (7) 
6B 256 (8) 32.(8) 237 (7) 19 (4) 
6C 12 (0.4) 2 (05) 5 (0.1) 0 
8 112 (3) 16 (4) 100 (3) 12 (3) 
14 336 (10) 53 ( 13) 276 (8) 35 (8) 
18A 9 (0.3) 1 (0.2) 13 (0.4) 1 (0.2) 
18B 0 0 2 (0.1) 0 
18C 85 (3) 8 (2) 76 (2) 16 (4) 
18F 7 (0.2) 1 (0.2) 4 (0.1) 0 
20 6 (0.2) 2 (0.5) 9 (0.3) 2 (0.5) 
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Serotypes Isolates detected by  
Quellung reaction n (%) 
Number detected by 
C-PCR n (%) 
Isolates detected by 
Quellung reaction n (%) 
Number detected by  
C-PCR n (%) 
31 6 (0.2) 1 ( 0.2) 8 (0.2) 2 (0.5) 
34 22 (0.7) 5 (1) 27(0.8) 4 (1) 
25/38 28 (0.8) 6 (1) 27 (0.8) 6 (1) 
10A 26 (0.8) 1 (0.2)  20 (0.6) 3 (0.7) 
11A 16 (0.5) 1 (0.2) 17 (0.5) 3 (0.7) 
11D 0 0 0 0 
12A 0 0 0 0 
12F 96 (3) 7 ( 2) 122 (4) 15 (4) 
15A 26 (0.8) 3 (0.7) 19 (0.6) 4 (1) 
15F 10 (0.3) 1 (0.2) 4 (0.1) 0 
15B 42 (1) 7 (2) 40 (1) 5 (1) 
15C 3 (0.1) 0 3 (0.1) 0 
16 48 (1) 4 (1) 63 (2) 5 (1) 
17F 31 (0.9) 8 (2) 36 (1) 1 (0.2) 
19A 267 (8) 33 (8) 320 (9) 37 (9) 
19F 198 (6) 21 (5) 187 (6) 31 (7) 
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Serotypes Isolates detected by  
Quellung reaction n (%) 
Number detected by 
C-PCR n (%) 
Isolates detected by 
Quellung reaction n (%) 
Number detected by 
 C-PCR n (%) 
22A/A 48 (1) 7 (2) 45 (1) 6 (1) 
23A 8 (0.2) 2 (0.5) 17 (0.5) 3 (0.7) 
23F 270 (8) 38 (9) 272 (8) 33 (8) 
33A 1 (0.03) 0 3 (0.1) 1 (0.2) 
33F 12 (0.4) 2 (0.5) 5 (0.1) 1 (0.2) 
37 3 (0.1) 1 (0.2) 2 (0.1) 0  
35B 17 (0.5) 4 (1) 7 (0.2) 2 (0.5) 
35F 6 (0.2) 0 5 (0.1) 0 
40 0 0 0 0 
44 0 0 0 0 
46 0 0 0 0 
47F 0 0 0 0 
7A 0 0 0 0 
7B 2 (0.1) 0 0 0 
7C 22 (0.7) 4 (1) 27 (0.8) 3 (0.7) 
7F 27 (0.8) 2 (0.5) 34 (1) 4 (1) 
9N 55 (2) 4 (1) 49 (1) 5 (1) 
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9L 1 (0.03) 0 0 0 
9V 106 (3) 13 (3) 89 (3) 17 (4) 
C-PCR neg. 115
a 
(3) 14
b 
(3) 130
c 
(4)
 
15
d 
(4) 
Total 3327 (100) 411 (100) 3391 (100) 419 (100) 
a
Quellung reaction results for 2008 (Serotypes by Quellung reaction (No. of isolates) = 10F (9), 11B (4), 11C (1), 11F (1), 12B (1), 13 (29), 17A (1), 19B (1), 21 
(3), 23B (9), 24 (1), 28 (1), 28 (3), 29 (23), 33D (15), 35A (1), 42 (1), 43 (1), 48 (4), NT (7).  
b
C-PCR– Conventional PCR negative for 2008 (Serotypes by Quellung reaction (No. of isolates) = 13 (6), 10F (1), 29 (3), 19B (1), 33D (2), NT (1) 
c
Quellung reaction results for 2009 (Serotypes by Quellung reaction (No. of isolates) = 10F (9), 11B (2), 11C (3), 11F (1), 12B (2), 13 (39), 19B (4), 21 (7), 23B 
(8), 24 (3), 27 (1), 28 (3), 29 (18), 33D (18), 35C (1), 48 (2), NT (8) 
d
C-PCR– Conventional PCR negative for 2009 (Serotypes by Quellung reaction (No. of isolates) = 13 (7), 10F (2), 23B (2), 35D (3), 35C (1) 
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Figure 9. Number of pneumococcal isolates tested by conventional PCR, by serotype and the cumulative percentages detected per 
reaction for 2008 national invasive pneumococcal disease surveillance isolates, South Africa (n=411) 
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Figure 10. Number of pneumococcal isolates tested by conventional PCR, by serotype and the cumulative percentages detected per 
reaction for 2009 national invasive pneumococcal disease surveillance isolates, South Africa (n=419) 
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3.3 Validation of real-time PCR serotyping assay 
3.3.1 Setting up of the assay using 2007 isolates 
A total of 66 isolates representing 22 serogroups/types targeted by the RT-PCR serotyping assay 
could be assigned a correct serotype using the assay. The results were 100% concordant with 
Quellung reaction and the C-PCR assay results. One control belonging to serotype 18F could not 
be amplified as it is not targeted in the RT-PCR serotyping assay, but it is targeted by the C-PCR 
as serogroup 18.  
The isolates used could be amplified when 10X and 100X diluted and, as expected, there was an 
increase in Ct-values in the 100X diluted samples compared with the 10X diluted samples. There 
was no significant difference in the Ct-values of the duplex reactions compared to the singleplex 
reactions (Table 5). 
3.3.2 Validation of the real-time PCR assay using 2008 and 2009 isolates  
Among 66 serotypes/groups tested (n=228), 29 serotypes/groups were true negatives upon 
completion of all 11 duplex reactions. Cross-reactions were observed in 4 serotypes/groups. The 
primers/probe combination for serotype 38 cross-reacted with serogroup 25; serotype 33A/F 
cross-reacted with serogroup 37; serotype 18B/C cross-reacted with serotype 18A and serotype 
9A/V cross-reacted with serotypes 9N/L. The sensitivity and specificity of the RT-PCR assay was 
100% (134/134) and 95% (89/94), respectively.  
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Table 5. Comparison of the cycle threshold (Ct) values of the singleplex and duplex reactions for 
the controls used in the validation of the real-time serotyping PCR assays (p=0.06 for 10X 
dilutions, and p=0.24 for 100X dilutions). 
 Serogroup/type Singleplex reactions Duplex reactions 
 
Mean Ct 
(10X dilution)* 
Mean Ct 
(100X dilution) * 
Mean Ct 
(10X dilution)* 
Mean Ct 
(100X dilution)* 
1 20.29 23.42 22.63 25.03 
3 20.74 23.92 22.58 26.24 
4 20.85 24.01 21.77 24.34 
5 19.99 23.19 20.62 24.38 
8 19.86 23.16 19.49 22.74 
14 20.26 23.66 19.21 22.42 
18A/B/C 22.83 26.16 24.19 27.57 
20 21.51 25.39 22.42 25.15 
38/25 19.97 22.67 21.55 25.89 
10A/B 20.67 27.81 21.21 24.81 
12A/B/F 18.47 21.71 18.81 22.21 
15A 19.57 22.50 20.44 24.03 
15B/C 19.76 23.38 20.21 23.44 
19A 20.70 23.90 20.33 23.28 
19B/F 19.62 22.79 20.37 23.67 
22A/F 20.50 23.81 21.44 23.86 
23F 20.05 23.49 22.09 25.80 
33A/F 20.03 23.24 21.50 24.88 
35B 22.36 25.76 26.03 29.59 
6A/B/C/D 21.30 26.05 18.80 22.31 
6C/D 20.05 22.82 17.42 20.86 
7A/F 19.02 22.35 21.36 24.53 
9A/V/L/N 18.72 22.12 22.06 24.89 
* mean of 3 results for isolates for each serotype tested in triplicate 
. 
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3.4 Serogroup 6 differentiation by C-PCR and RT-PCR assays 
The results for serogroup 6 differentiation by C-PCR corresponded with the Quellung reaction 
results for serotypes 6A (n=5), 6B (n=5) and 6C (n=5) surveillance isolates from 2007. Serotype 
6B isolates had a 155 bp band size, while for serotype 6A no serotype-specific band was observed 
as expected. The internal control of 250 bp was visible on all isolates tested. For serotype 6C, the 
two sets of primer pairs i.e. inner set and outer set, were tested on 5 isolates (6C) from 2007 
isolates separately, which gave the product size of 308 bp and 359 bp respectively. Both these 
primer sets could detect serotype 6C effectively with the difference only in band sizes. Therefore, 
for all subsequent reactions, only the outer primer pair set; wciNβS1 and wciNA2, with a product 
size of 359 bp was used because of the better band sizes resolution with the 250 bp band for 
serogroup 6 controls (Figure 11.  
 
 
 
Figure 11. An agarose gel representation of the multiplex reaction for differentiation of 
serogroup 6 serotypes (M=100 bp molecular marker, 6A=no band, 6B=155 bp and 6C=359 bp) 
stained with ethidium bromide and viewed under ultraviolet light.  
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The results obtained for the two duplex reactions and one multiplex reaction for 2008 (n=62) and 
2009 (n=49) isolates were 100% concordant with the Quellung reaction results. Of 178 serogroup 
6A and 6B isolates from 2010 surveillance, 167 (41%) were assigned serotype 6B, while only 11 
(3%) isolates were assigned serotype 6C corresponding to the Quellung reaction results. There 
were no isolates identified as serotype 6D (Table 6).  
 
The reaction for differentiating serogroup 6 serotypes was included in the 11 duplex reactions of 
the RT-PCR assay. Using this assay, serotypes 6A/6B could be distinguished from serotypes 
6C/6D. Fifteen controls for serotypes 6A (n=5), 6B (n=5) and 6C (n=5) from 2007 used for the 
initial validation of the reaction were 100% concordant with the Quellung reaction results as 
serotypes 6A/6B or 6C/6D. The isolates assigned as serogroup 6 from 2008 (n=62) and 2009 
(n=49) by the C-PCR and the Quellung reaction, were further confirmed by the RT-PCR assay. 
Of 408 isolates from 2010 surveillance, 167 and 11 isolates were assigned as serotypes 6B and 
6C, respectively, by the Quellung reaction. While screening for serotype 6D on serotype 6B and 
6C isolates received in 2010, the real-time PCR assay confirmed serotype 6B isolates as 6A/B, 
while 6C isolates were assigned as 6C/D (Table 6). 
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Table 6. Summary of serogroup 6 differentiation results by the Quellung reaction, conventional 
and real-time PCR serotyping assays, South Africa.  
3.5 Use of molecular serotyping methods for 2010 national IPD surveillance of culture-
negative samples 
Identification of pneumococcus by lytA RT-PCR was a useful tool in identifying the organism in 
culture-negative samples. The lytA Ct-value and the corresponding serotype Ct-value did not 
differ from each other by more than 4 Ct-value‟s. A summary of all results for culture-negative 
samples is shown in Table 7  
3.5.1 Non-viable transport medium samples  
Overall, 299 NVTMs were processed. C-PCR and RT-PCR assays were performed on 266 
available samples. Of the 33 samples processed using the RT-PCR assay only, 73% (24/33) could 
be assigned a serotype. The C-PCR assigned a serotype to 32% (85/266). RT-PCR confirmed a 
serotype for 94% (80/85), however could not confirm serotypes for five samples with serotypes 
11A, 17F and 23A as these serotypes were not targeted by the RT-PCR primers/probe sets. RT-
PCR added 68% (123/181) serotyping data to the remaining samples that could not be assigned a 
serotype by C-PCR. Using both C-PCR and RT-PCR assays, 78% (208/266) of NVTMs were 
assigned a serotype. A lytA Ct-value of ≤26 accounted for 82 samples while the remaining 184 
samples had a lytA Ct-value of >26. C-PCR and RT-PCR assigned serotypes to 72% (59/82) and 
Year No. of 
isolates 
Quellung reaction Real-time PCR Conventional PCR 
2007 15 6A (5), 6B (5) 6C (5) 6A (5), 6B (5) 6C (5) 6A/B (10), 6C/D (5) 
2008 62 6A (28), 6B( 32), 6C (2) 6A (27), 6B (32), 6C (2) 6A/B (59), 6C/D (2) 
2009 49 6A (30), 6B (19) 6A (30), 6B (19) 6A/B (49) 
2010 178 6B (167), 6C(11) 6B (167), 6C(11) 6A/B (167), 6C/D (11) 
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90% (74/82), respectively, of samples with lytA Ct-values ≤26 [59/82 (72%) vs. 74/82 (90%), 
p=0.003]. For samples with a lytA Ct-value >26, C-PCR and RT-PCR assigned serotypes to 14% 
(26/184) and 70% (129/184), respectively [26/184 (14%) vs. 129/184 (70%), p<0.001].  
 
Of 299 NVTMs, a culture was received for 22% (n=66) at a later stage. Of these, C-PCR and RT-
PCR had assigned 62% (41/66) of cases the same serotypes as the Quellung reaction. 17% of 
(11/66) samples that were negative on both PCR assays were serotypes presumably detected by 
both PCR assays as determined by the Quellung reaction. These were serotypes 5, 8, 14, 11A, 
15F, 16F, 22F, 23F, 25A, 35F and 7C (lytA Ct-value range=26-37, median=33). An additional 6% 
of samples (4/66) had discordant results, where RT-PCR assigned them as serotype 14, 19A, 23F 
and 6, while the Quellung reaction assigned these samples as serotypes 35B, 1, 9V and 9V, 
respectively (lytA Ct-value range=24-38, median=32). For these, the Quellung reaction results 
were used for final analysis. Overall, 15% of samples (10/66) with a lytA Ct-value of >26 
(range=28-37, median=31) belonged to serotypes not included in RT-PCR assay hence negative 
for both PCR assays.  
3.5.2 Clinical specimens (cerebrospinal fluid, blood and pleural fluid specimens)  
40 CSFs were identified as positive for the lytA gene and the C-PCR assay assigned a serotype to 
55% (n=22) of these samples. RT-PCR confirmed 86% (19/22) of these serotypes. The 3 
serotypes that could not be confirmed by RT-PCR were serotypes 11A, 17F and 34 and are not 
targeted by the RT-PCR primers/probe sets. RT-PCR added serotyping data for meningitis cases 
for 67% (12/18) of the remaining specimens. Using the two assays, 85% (34/40) of 
pneumococcal meningitis cases could be assigned a serotype. C-PCR and RT-PCR assigned 
serotypes to 71% (17/24) and 79% (19/24) (p=0.51), respectively of specimens with lytA Ct-value 
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≤26. For specimens with a lytA Ct-values >26, C-PCR assigned a serotype to 31% (5/16), while 
RT-PCR assigned 75% (12/16) (p=0.01) (Table 7). For five cases for which a “culture-negative” 
CSF specimen had been received, an isolate was received at a later stage. The Quellung reaction 
results for cultures were 100% concordant with the C-PCR and RT-PCR assays results for the 
matched clinical specimen.  
 
Blood (n=10) and a pleural fluid (n=1) specimen had lytA Ct-values of <26. The C-PCR was able 
to assign serotypes to 82% (9/11) of these specimens. No further serotyping results could be 
added using the real-time PCR, and RT-PCR was not completed on all reactions on 2 specimens, 
due to shortage of DNA extract. Six blood specimens were also culture positive at a later stage 
and the Quellung reaction results for cultures were 100% concordant with both PCR serotyping 
assays results for the matched clinical specimen.  
 
3.5.3 Beep-positive, subculture-negative blood culture bottles 
The Ct-values of the lytA RT-PCR ranged from 13-26 for beep-positive blood cultures and 
therefore these samples (n=154) demonstrated high bacterial loads. The majority of these samples 
could be assigned a serotype (94%, 145/154) using C-PCR. Of these 93%, (135/145) were 
confirmed by RT-PCR. RT-PCR did not detect 10 serotypes that are not part of its repertoire 
[serotypes 7C (n=4), 17F (n=4), 16F (n=1) and 35F (n=1)]. The remaining 9 samples that could 
not be assigned a serotype by either PCR methodology were presumed to be of serotypes not 
targeted by either of the C-PCR and the RT-PCR serotyping assays. Overall, 94% (145/154) of 
bacteraemia cases were assigned a serotype using both assays. Five blood cultures showed the 
presence of mixed infection by simultaneous identification of two different serotypes. While the 
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C-PCR assays detected only one serotype, the RT-PCR detected the presence of the additional 
serotype. Co-infection with serotype 19A was found in three samples also assigned as serotypes 
1, 5 and 4. The remaining two samples were assigned a serotype 19F and 23F, and were co-
infected with serotype 1 and 6A/B respectively. Viable isolates were available retrospectively for 
16 blood cultures that were initially identified as culture negative. The Quellung reaction results 
for cultures were 100% (16/16) concordant with the C-PCR and/or RT-PCR assays results for the 
matched blood culture sample. 
 
3.6 Sensitivity of PCR assays for culture-negative samples 
There was no statistical difference in assigning of serotypes using the C-PCR and the RT-PCR 
assay for blood cultures [145/154 (94%) vs. 135/154 (88%), p=0.05] and blood/pleural fluid 
specimens [9/11 (82%) vs. 7/11 (64%), p=0.35]. Among CSFs, RT-PCR was more sensitive than 
C-PCR [22/40 (55%) serotypes detected by C-PCR vs. 31/40 (76%) by RT-PCR, p=0.03]. 
Similarly, for NVTMs RT-PCR was more sensitive than C-PCR [85/266 (32%) vs. 203/266 
(76%), p<0.001] (Figure 12). 
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Figure 12. Percentage of serotype yield in culture-negative samples; blood cultures (n=154, 
median lytA Ct-value=24), blood and pleural fluid specimens (n=11, median lytA Ct-value =16), 
CSF specimens (n=40, median lytA Ct-value =23) and non-viable transport medium samples 
(NVTMs, n=266, lytA Ct-value median=29) obtained by conventional and real-time PCR 
serotyping assays, South Africa, 2010.  
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Table 7. Culture-negative samples received as part of national invasive pneumococcal disease surveillance and serotyped using the 
conventional multiplex and real-time PCR serotyping assays in South Africa, 2010.  
 
Sample type Number of 
samples 
Serotyped by 
C-PCR (%) 
Serotyped by 
RT-PCR (%) 
lytA Ct-value 
range (median) 
C-PCR pos. 
(%) (lytA ≤26) 
C-PCR pos. (%) 
(lytA >26) 
RT-PCR pos. (%) 
(lytA ≤26) 
RT-PCR pos. 
(%). (lytA >26) 
Blood 
cultures 
154 145 (94) 135 (88) 13-26 (24) 145/154 (94) 0 (0) 135/154 (88) 0 (0) 
CSFs
a
 40 22 (55) 31 (76) 17-36 (23) 17/24 (71) 5/16 (31) 19/24 (79) 12/16 (75) 
Blood/pleural 
fluids 
11 9 (82) 7 (64) 11-23 (16) 9/11 (82) 0 (0) 7/11 (64) 0 (0) 
NVTMs
b
 266 85 (32) 203 (76) 13-37 (29) 59/82 (72) 26/184 (14) 74/82 (90) 129/184 (70) 
a
CSFs
 – Cerebrospinal fluids  bNVTMs–non-viable transport medium samples 
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3.7 Use of molecular serotyping assays for special studies 
3.7.1 SARI surveillance study 
The lytA quantitative real-time PCR was performed on 5130 blood specimens from patients 
hospitalised with severe pneumonia from May 2009 to December 2010. Pneumococcal DNA was 
detected in 7% (370/5130) of patients of all age groups. The Ct-values of the lytA RT-PCR ranged 
from 22-40 (median 34). Serotypes were determined for 52% (190/368) of specimens by RT-
PCR. Two specimens were not available for serotyping. The prevalent serotypes were 19A (n=43, 
12%), 1 (n=35, 9%) and 6A/B (n=23, 6%) (Figure 13).  
 
Figure 13. Pneumococcal serotype distribution identified in lytA-positive blood specimens from 
the severe acute respiratory illness (SARI) surveillance study (n=190, median lytA Ct-value =34) 
determined by the real-time PCR assay for all age groups, South Africa, 2009-2010 
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3.7.2 Empyema study 
A total of 42 pleural fluids were received for the study from September 2009 through to May 
2011. Pneumococcal DNA was detected in 45% (19/42) of cases. The RT-PCR assay was 
performed on all 19 specimens and a serotype was determined for 95% (18/19) of empyema cases 
(lytA Ct range=17-37, median Ct=28) using this assay. The C-PCR assay was performed on 14 of 
these specimens and a serotype was determined for 4/14 (29%) specimens of which all had a lytA 
Ct-value of <26 (range=18-24, median=22). The C-PCR assay assigned serotypes to all 
pneumococci with a lytA Ct-value of ≤26. The RT-PCR assay results for four samples for which 
both assays were performed were 100% concordant with results previously assigned by the C-
PCR assay. Of the 19 lytA positive specimens, serotypes 6A/B (n=8, 42%), 19A (n=3, 16%), 23F 
(n=3, 16%), 14 (n=2, 11%) and 1 (n=2, 11%) were identified in these specimens.  
3.8 Application of molecular-based serotyping techniques to determine serotype 
distribution  
3.8.1 Nationwide invasive pneumococcal diseases surveillance programme 
A summary of results for all culture-negative samples received is shown in Table 7. There was no 
significant difference in the distribution of predominant serotypes between isolates and culture-
negative samples. For isolates received in 2010, common serotypes identified were serotypes 1 
(369/2859), 19A (301/2859), 6A (232/2859), 23F (208/2859), 14 (168/2859), 4 (166/2859), 6B 
(166/2859), 19F (143/2859) and 12F (143/2859) accounting for 66% (1896/2859) of all serotypes 
identified (Figure 14). The same serotypes; serotype 1 (65/395), 19A (36/395), 6A (27/395), 23F 
(21/395), 14 (26/395), 4 (35/395), 6B (12/395) 19F (12/395) and 12F (16/395) were common in 
culture-negative samples, accounting for 67% (250/395) of all serotypes identified (1896/2859 vs. 
250/395, p=0.23).  
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There was no significance difference in the distribution of the 11 most prevalent serotypes among 
individuals <5 years of age between isolates and culture-negative samples (508/647 [78%] in 
isolates vs. 48/65 [74%] in culture-negative samples, p=0.38). However, serotypes 6A and 6B 
were commonly identified in cultures, whereas in culture-negative samples, serotypes 14 and 4 
were more commonly identified (Figure 15). Similarly, in individuals ≥5 years of age, there was 
no significant difference in the distribution of the 11 most prevalent serotypes (Figure 16) in 
cultures and culture-negative samples using the Quellung reaction and the PCR-based assays, 
respectively (1504/2120 in isolates vs. 225/317 in culture-negative samples, p=0.99). Age was 
not available for 105/3254 (3%) samples with serotyping results.  
 
PCV7 serotypes accounted for 35% (992/2859) and 28% (112/395) of all serotypes identified in 
isolates and culture-negative samples, respectively (992/2859 vs. 112/395, p=0.01) (Figure 17). 
This was also the case when serotype 6A (an important cross-protected serotype in PCV7) was 
included, accounting for 43% (1222/2859) and 36% (145/395) of all serotypes in culture-positive 
samples and culture-negative samples, respectively (1222/2859 vs. 145/395, p=0.02).  
 
PCV13 serotypes accounted for 73% (2074/2859) of all serotypes identified from culture-positive 
samples received in 2010. PCV13 serotypes accounted for 68% (267/395) of serotypes identified 
in culture-negative samples (2074/2859 vs. 267/395. p=0.04). 
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Figure 14. Pneumococcal serotype distribution from isolates (n=2859) and culture-negative samples (n=395) determined by the 
Quellung reaction and PCR-based serotyping assays respectively, for all age groups, South Africa, 2010 
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Figure 15. Predominant serotypes identified in invasive pneumococcal disease cases in children <5 years from isolates (n=647) and 
culture-negative samples (n=65) reported to the national surveillance and serotyped by Quellung reaction and PCR assays respectively, 
in South Africa, 2010. 
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Figure 16. Predominant serotypes identified in invasive pneumococcal disease cases in individuals ≥5 years from isolates (n=2120) 
and culture-negative samples (n=317) reported to the national surveillance and serotyped by Quellung reaction and PCR assays 
respectively, in South Africa, 2010. 
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Figure 17. Distribution of PCV7 serotypes among isolates (35%, 992/2859) and culture-negative (28%, 112/395) samples for all age 
groups in South Africa, 2010. 
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3.8.2 Severe Acute Respiratory Illness surveillance programme 
An overall non-significant decrease (p=0.47) was observed in lytA positivity from 8% (151/2005) 
in 2009 to 7% (219/3125) in 2010 for the SARI surveillance programme. From 2009 to 2010, 
there was a significant reduction the proportion of lytA positivity in children <2 years (n=1696) 
admitted with severe pneumonia, from 6% (43/723) to 4% (36/973), respectively (p=0.03). PCV7 
serotypes accounted for 29% (23/78) of serotypes identified in children <2 years in 2009-2010. 
There was no significant difference in the proportion of PCV7 serotypes in children <2 years 
between 2009 and 2010 (14/43 in 2009 vs. 9/35 in 2010, p=0.51). The proportion of PCV7 
serotypes differed non-significantly for patients in age groups <2 (23/78), 2-4 (2/18) and ≥5 
(61/272) years of age (p=0.19) (Table 8). PCV13 serotypes accounted for 46% (171/368) of all 
cases in 2009-2010.  
 
Of the 1696 children <2 years, 829 children were eligible to receive PCV7 55% (456), 29% (240) 
and 16% (133) had received 0, 1 or 2-3 doses, respectively at least 14 days before onset of 
symptoms of severe pneumonia (Table 9). 40 cases of severe pneumonia due to pneumococcus 
were identified in all children <2 years eligible for PCV7 from May 2009-December 2010 in SA. 
In this group, pneumonia due to a PCV7 serotype accounted for 33% (7/21), 20% (3/15) and 0% 
(0/4) of cases in children who had received 0, 1, or 2-3 doses of PCV7, respectively (p=0.31).  
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Table 8. S. pneumoniae lytA positivity in patients hospitalised with severe pneumonia, May 2009 
through December 2010 in South Africa (n=370).  
Age in 
years 
lytA-positive cases  
n/N (%) 
p-value  
 
Cases with PCV7serotypes  
n/N (%) 
p-value  
 
 2009 2010  2009 2010  
<2 43/721 (6) 36/974 (4) 0.03 14/43 (33) 9/35* (26) 0.51 
2-4 12/157 (8) 6/187 (3) 0.06 0/12 (0) 2/6 (33) 0.04 
≥5 96/1137 (8) 177/1979 (9) 0.63 25/95* (26) 36/177 (20) 0.26 
Total 151/2015 (7) 219/3140(7) 0.48 39/150 (26) 47/218 (21) 0.32 
* 2 lytA positive samples not available for serotyping. 
 
Table 9. S. pneumoniae lytA positivity and 7-valent pneumococcal conjugate vaccine (PCV7) 
serotypes in children <2 years hospitalised with severe pneumonia, by PCV7 vaccination status, 
May 2009 through December 2010, South Africa.  
No. of PCV7 doses lytA positive cases 
 n/N (%)  
Cases with PCV7 types  
n/N (%) 
0 dose 21/456 (5) 7/21 (33) 
1 dose 15/240 (6) 3/15 (20) 
2 or 3 doses 4/133 (3) 0/4 (0) 
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4 Discussion 
S. pneumoniae serotypes are highly diverse, with 93 serotypes described to date. The high 
diversity of serotypes and high genetic similarity within serogroups poses a great challenge in 
assigning a correct serotype using either molecular or immunological assays. Even the traditional 
immunological reactions used have proven to be ineffective in distinguishing between highly 
similar serogroups/types. Unlike other pathogens that CRDM conducts national surveillance on, 
such as H. influenzae and N. meningitidis, comprising of highly distinguished 6 serotypes and 12 
serogroups, respectively, serotyping of the pneumococcus remains a challenge using either 
method. Therefore any assay, whether molecular or immunological, will be a trade-off between 
number of serotypes detected versus time, complexity of the assay, technical expertise and cost 
required to perform the assay. 
 
The present study reports the use of molecular-based serotyping for S. pneumoniae in SA. 
Accurate serotype determination is a crucial factor in the PCV era, as vaccine developments rely 
on serotyping data. The emergence of vaccine-replacement serotypes post routine usage of PCV7 
further emphasises the need for rapid and accurate serotyping data. The Quellung reaction is not 
feasible in poor-resourced settings, because of the high cost of the assay. Even in well-equipped 
laboratories, the Quellung reaction remains a challenge because of the technical expertise needed, 
subjectivity in interpretation of results and the complexity of the assay. An additional major 
draw-back of the Quellung reaction is that it cannot be used for serotyping of culture-negative 
samples, as it is culture dependent. 
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The use of molecular serotyping for culture-negative samples added 8% serotyping data to the 
national IPD surveillance in SA for 2010. As a result of this study, the C-PCR and RT-PCR 
serotyping assays were implemented for routine use in South African IPD surveillance for 
culture-negative samples.  
 
Our study showed that the C-PCR assay is a feasible method that could be applied in SA for 
accurate serotype determination. The assay showed 100% specificity and sensitivity for isolates. 
The results were 100% concordant with the Quellung reaction results, with only <1% personal 
errors that could be easily resolved. For culture-positives, the assay was sufficiently sensitive as 
cultures can be controlled for sufficient DNA concentrations during crude DNA extraction. The 
random selection of isolates was an adequate representation of serotypes circulating in SA. The 
C-PCR assay assigned a serotype to 97% of 2008 and 96% of 2009 isolates randomly selected for 
serotyping. Based on the Quellung reaction serotypes, we estimate that of all 2008 and 2009 
isolates, >96% for each year would be able to be assigned a serotype or serogroup using the C-
PCR assay. This finding is important in that this assay independently could assign a serotype or a 
serogroup to the majority of South African surveillance IPD isolates, without use of the Quellung 
reaction, although some would not be resolved to specific types. The accuracy, coverage rate and 
specificity obtained when using the protocol for US isolates was similar to what was obtained 
elsewhere in Africa [64], Brazil [63] and in Korea [188]. The results showed C-PCR can be used 
as a reliable alternative or supplement to the Quellung reaction for viable isolate serotyping. This 
supports the fact that this multiplex C-PCR assay can easily be introduced in many laboratory 
settings with viable cultures [60].  
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The most prevalent disease-causing serotypes in SA i.e. serotypes 1, 19A, 6A, 6B, 14, 23F and 
19F were detected in the first three reactions. The majority of isolates could be assigned a 
serotype within the first few reactions, decreasing the number of isolates as the reactions proceed 
sequentially. As Pai et al, [60] recommended, the first three reactions could be performed 
simultaneously, to allow for rapid detection of serotypes, while the last three reactions could be 
done separately, with a limited number of isolates remaining. In Korea, a similar finding was 
observed, where at least 60% of isolates were assigned a serotype by the end of reaction 3 [188].  
 
The grouping of primers and the reactions can be re-arranged to improve the efficiency of 
serotype yield per region, considering band size resolutions between serotypes in the same 
reaction. In the current study, no rearrangement of the serotypes within a reaction was necessary. 
However reaction 3 which contains serotype 1, the leading serotype in SA in adults, was 
performed sequentially after reaction 1, to allow for more isolates to be serotyped using the first 
two reactions.  
 
In Spain, modification of the CDC protocol increased serotyping yield from 63% to 73% within 
the first three reactions [189]. The CDC developed a protocol for African regions (clinical 
specimens), based on the majority of serotypes reported to be circulating in Africa and Morais et 
al [64] modified the Pai et al [60] scheme for African specimens. However, these modified 
schemes were not used in this study because the majority of serotypes included in the first three 
reactions are less common in SA than other African regions. The US protocol for isolates from 
the ABC surveillance data had better serotype coverage in the first three reactions for South 
African isolates, hence it was used. Similarly, the revised protocol for detecting 40 
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serotypes/groups (CDC 33 serotypes plus serotypes 31, 21, 24, 39, 10F, 23B, 13), consisting of 8 
reactions was not used because the additional reactions detected <1% of serotypes (using 2008 
and 2009 surveillance isolates serotypes) while adding two more reactions and therefore 
increasing the cost and time of the assay. The distribution of serotypes is likely to change due to 
vaccine pressure, therefore new protocols which cover more serotypes may be useful going 
forward and new primer sets can be added to the established method. 
 
The C-PCR assay was proven to be less subjective and required less technical skill, compared to 
the Quellung reaction methodology. The methodology was also suitable for large scale 
preparation, by allowing for PCR setup of >400 isolates in one reaction and obtaining at least 
40% of serotypes in <5 hours from PCR preparation to gel electrophoresis results. C-PCR can be 
used for carriage isolates with an added advantage of detecting multiple colonisations [190;191] 
and for other non-invasive pneumococcal infections such as otitis media [192].  
 
Despite the many benefits of the C-PCR assay, it is associated with several disadvantages. The 
assay currently cannot identify all known pneumococcal serotypes. Although most of the 
serotypes not included are not historically epidemiologically significant, in the era of replacement 
serotypes and vaccine-escape recombinants, monitoring of these serotypes may become more 
important. Recent protocols published [68] have increased serotype coverage, however, not all 93 
serotypes are included. In this study, 3% from 2008 and 4% from 2009 of selected isolates 
belonged to serotypes not included in the assay. Although this percentage is small, concerns of 
this percentage increasing in SA due to serotype replacement warrants continued serotype 
surveillance and adaptation to new protocols.  
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A further disadvantage is that most of the serotypes can only be resolved to genetically related 
serotypes (e.g. serotypes 18A/B/C/F, 7A/F and 38/25), and cannot be resolved any further as the 
Quellung reaction would, using serotype-specific factor sera. This poses a challenge in vaccine 
effectiveness studies, where one serotype in the genetically related group is included in one of the 
vaccine formulations and the other is not included. For example, for serogroup 18, serotype 18C 
is in PCV7, while serotypes 18A, 18B and 18F are not.  
 
These limitations may be overcome by designing serotype-specific primers to detect the most 
prevalent serotypes, instead of detecting a serogroup. This however, might be challenging due to 
the high genetic similarities between serotypes belonging to the same serogroup or cluster. 
Training should be focused on DNA extraction procedures, to minimise personal errors such as 
cross-contamination of stored cultures, as encountered in this study. The accuracy in interpreting 
the results (band sizes) can be achieved by including serotypes that give clear band resolutions in 
a reaction i.e. sufficient distance between band sizes for serotypes included in the reaction to be 
assigned accurately.  
 
Although the C-PCR assay was successfully implemented, advancement due to new technologies 
that further increase the uses and advantages of PCR assays were considered.  
Real-time PCR has advantages over conventional PCR in that it is faster by allowing for results to 
be analysed in real-time as the product accumulates [69]. In addition, it has increased sensitivity 
for samples with low DNA concentrations [33;34].  
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The RT-PCR assay used for serotyping of S. pneumoniae isolates demonstrated 100% sensitivity 
for serotyping of cultures, similar to the C-PCR assay and the Quellung reaction. Bacterial 
cultures have abundant organism and therefore higher concentrations of DNA. In Italy [34], a 
similar finding for cultures was observed; both the conventional and the real-time serotyping 
assays displayed 100% sensitivity for isolates. Due to the time-consuming and laborious nature of 
the singleplex reactions, the method described by Azzari et al. was adapted to duplex reactions. 
Reactions were performed in both singleplex and duplex formats to determine if there was loss of 
sensitivity in the duplex assay compared to the singleplex assays. There was no loss in sensitivity 
when using the duplex assay compared to the singleplex assay. The original [34] 21 singleplex 
reactions were successfully modified in to 11 duplex reactions, thereby reducing the time and cost 
required to perform the assay. Based on the Quellung reaction serotypes, we estimate that of all 
2008 and 2009 isolates, ≥91% for each year would be able to be assigned a serotype or serogroup 
using the RT-PCR assay.  
 
For isolates both the C-PCR and RT-PCR assays had high sensitivity; however, there were cross-
reactions detected in the RT-PCR assay not reported by Azzari et al [34] between serotypes 25 
and 38, 33A/F and 37 and serogroup 18 serotypes (except serotype 18F). In the sequential 
multiplex PCR from CDC [60;68], these cross reactions were reported. Immunological reactions 
cannot distinguish between serogroups 38 and 25 [38] and it was not surprising that these 
serogroups cross-reacted in both PCR assays. Serotype 9A/V primers cross-reacted with serotype 
9N and 9L, and this finding was also observed in the RT-PCR developed by Tarrago et al [70], 
although different primer sequences were used in this study. Pai et al. recognised and reported the 
cross-reactivity for C-PCR, however, they were not described in the RT-PCR protocol described 
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by Azzari et al [34]. The cross reaction between serogroup 9 serotypes in RT-PCR assay was 
taken as false positive in specificity calculations as these serotypes can be distinguished in C-
PCR as serotypes 9A and 9N/L. The cross-reactions were detected when the RT-PCR assay was 
validated as part of this study. Therefore, results in this study were reported accordingly to reflect 
the inability of the assay to differentiate certain serotypes e.g. serotype 33A/F positive samples 
are reported as positive for serotypes 33A/33F/37, and serotype 38 positive samples are reported 
as positive for 38/25. This finding is consistent with what was reported in Italy [73], in a different 
study where serotype 18B/C was reported as serogroup 18. Considering these findings, the RT-
PCR serotyping assay displayed 95% specificity based on the original Azzari protocol [34] and 
accounting for known cross-reactions. The cross-reacting serotypes are highly similar in their cps 
biosynthetic loci and belong to the same sub-clusters [38]. Thus designing serotype-specific 
primers is difficult; hence these serotypes cannot currently be differentiated.  
 
A limitation of the RT-PCR assay used is that many of the genetically related serogroups could 
not be resolved to individual serotypes. While the same scenario was observed for the C-PCR 
assay (15B/C, 18, 9N/L, 38/25, 22A/F and 3A/F), the number of serogroups that could not be 
resolved to individual serotypes was increased in the RT-PCR serotyping assay i.e. serogroups 9, 
12A/B/F, 15, 6A/B, 6C/D, 7A/F, 10A/B, 18A/B/C, 19B/F, 22A/F and 33A/F. As in the C-PCR 
assay, the assay could be enhanced by incorporating, where possible, primers and probes 
targeting specific serotypes. However, this would increase the time and cost of the assay. For 
isolates however, this is not a limitation as the Quellung reaction can be used to resolve majority 
of closely-related serotypes.  
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Although the primers for serogroup 6 differentiation are not included in the C-PCR assay 
described by Pai et al. (only the serotype 6C differentiation reaction is included), an additional 
reaction can easily be incorporated into the assay. Serogroup 6 differentiation by conventional 
PCR (original Jin et al [156] protocol and the modified protocol) yielded results that were 100% 
concordant with the Quellung reaction results using factor sera 6b, 6c and 6d for detecting 
serotypes 6A, 6B and 6C respectively. The factor sera 6b used was the modified Danish antisera 
[58] developed after discovery of serotype 6C [43;154]. The newly validated factor sera 6d was 
used for serotype 6C [157]. After the discovery of serotype 6C, all surveillance isolates 
previously typed as serotype 6A and corrected using the new antisera for 6C [161], were 
retrospectively serotyped using conventional PCR  
 
The RT-PCR assay used can only distinguish serotypes 6A/B from 6C/D. For a PCV7 
effectiveness study, this may be acceptable since serotype 6A is cross-protected by serotype 6B 
antigens in PCV7 [166]. Several developed countries have reported this cross-protection, 
however, in an African setting with a high HIV prevalence, this might not hold true and resolving 
these serotypes might still be crucial. Furthermore, in the era of PCV13, where serotype 6C 
disease is cross-protected by 6A [176], differentiating serotype 6D from 6C is likely to be of 
importance. An increase in the prevalence of serotype 6C among vaccinated and unvaccinated 
populations was observed in countries with routine use of PCV7 [90;159;162-164]. However, in 
SA the prevalence of serotype 6C is still low. This was similar to what was reported two years 
earlier (2008) in SA isolates [161]. Serotype 6D was not detected in the 3-year period 
surveillance isolates screened. For 2010, all serotype 6B and serotype 6C samples were screened, 
while for 2008-2009, only a randomly selected proportion of culture-positive samples and all 
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culture-negative samples belonging to serogroup 6 were screened. To date, no serotype 6D has 
been reported in any African country performing surveillance for IPD. Continued surveillance of 
serogroup 6 serotypes is needed to screen for an increase in prevalence of serotype 6C, and to 
screen for an emergence of serotype 6D in SA. 
 
DNA concentration had an impact on yield of serotypes using the C-PCR assay. A higher lytA Ct-
value was associated with a decrease in serotype yield by C-PCR on all sample types. The higher 
sensitivity of RT-PCR was particularly useful for the serotyping of NVTMs, with low bacterial 
loads (average lytA Ct-value of >26). The serotype yield increased 2-fold by the use of RT-PCR 
compared to C-PCR (p≤0.001). For NVTMs, there was an increase from 14% serotype yield in 
specimens with high lytA Ct-values (>26) compared to >70% serotype yield in specimens with 
low lytA Ct-values of ≤26 using the C-PCR assay. Furthermore, an increase from 32% to 76% in 
serotype yield was observed from C-PCR to RT-PCR in serotyping of NVTMs, respectively. 
Azzari et al reported an increase from 64% to 91% in serotype yield for culture-negative samples 
using C-PCR and RT-PCR, respectively [34]. Using RT-PCR alone, 93% of CAP cases in Italian 
children were assigned a serotype using the Azzari et al scheme [73]. Similarly, a serotype could 
be assigned to 80% of CAP cases from children <5 years using RT-PCR of alternative 
primers/probe sets in a different region in Italy [193]. 
 
Overall, 30% of pneumococcal meningitis cases which the C-PCR assay could not serotype were 
assigned a serotype using the RT-PCR assay. Independently, the C-PCR and RT- PCR assays 
could assign a serotype to pneumococcal meningitis cases for 55% and 78%, respectively. In 
Togo and Burkina Faso, the conventional multiplex PCR assigned a serotype to 90% of 
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meningitis cases directly from CSFs [66]. However, 64% of the CSFs used had cultures available, 
and therefore had sufficiently high DNA concentrations for detection by the conventional PCR 
assay. Similarly, in this study, blood and pleural fluid specimens, had a high serotype yield by 
both PCR-based serotyping assays, and all had a Ct-value of ≤26. A culture was obtained at a 
later stage for the majority of blood specimens used in this study, accounting for low Ct-values 
observed. However, the numbers are small to emphasize the strength of PCR serotyping assays in 
these specimens.  
 
Both the C-PCR and RT-PCR serotyping assays had high serotype yields on „beep-positive‟ 
blood cultures (≥86%). This is due to the nature of these specimens, in which bacterial growth 
has occurred, resulting in high DNA concentrations. This is confirmed by the low lytA Ct-values 
(≤26) of these samples. Therefore the lower sensitivity of C-PCR in comparison with RT-PCR 
was not problematic for these specimens. 
 
The retrospective receipt of cultures for which culture-negative specimens were received provides 
an opportunity to assess serotyping results for these specimens. Serotyping results from PCR 
assays on clinical specimens (blood cultures, CSFs, and blood specimens) were 100% concordant 
with the Quellung reaction results for the corresponding cultures for serotypes included in the 
PCR assays. However, for NVTMs, only 62% could be assigned a serotype fully concordant with 
the Quellung reaction results using either or both PCR assays. 21% of the remaining samples 
(negative on PCR-based serotyping assays) belonged to serotypes detectable by one or both PCR 
assays, with Ct-values theoretically considered low enough for detection in the RT-PCR 
serotyping assay. However, it was found that samples with borderline Ct-values of 37-40 might 
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not have sufficient DNA for detection by the RT-PCR assay. The lytA detection and RT-PCR 
serotyping assays Ct-values differed by ±4 units, thereby resulting in discrepancies between the 
two PCRs. Another explanation for this discrepancy might be that the original sample sent by the 
regional laboratory was not the same as the second sample sent for a particular patient. Thus 
although the NVTMs are lytA positive, it might not be the same sample as later received for 
Quellung reaction. Some laboratories send repeat cultures within a limited time period (<2 
weeks), while other laboratories take longer in sending repeat cultures upon request, which 
increases the chance of error. Regular training on sub-culturing on Dorset media from agar plates 
at regional laboratories and reviving of NVTMs to obtain culture or sufficient DNA concentration 
is still warranted in SA. It is also possible that these strains have undergone certain mutational 
events, altering the primer binding site in the cps loci which resulted in no amplification/binding 
of the PCR primers. This needs to be explored further using gene sequencing.  
The predominant serotypes were not different between culture-negative samples and culture-
positive samples. Serotypes 14, 19F, 4, 6A/6B, 19A, 23F and 4 were the leading serotypes in 
children <5 years, while in individuals ≥5 years, both phenotypic and the molecular serotyping 
assays identified serotypes 1, 19A, 4, 6A, 23F, 12F and 14 as predominant. Thus, there does not 
seem to be serotypes specifically associated with culture-negative specimens and serotype did not 
influence the viability of the organism in the specimens in our study.  
 
The most commonly identified paediatric serotypes were serotypes 14, 19F, 4, 6A/6B and 19A. 
The prevalence of serotype 14 in younger children has been reported, accounting for 23-25% of 
IPD cases in children compared with 14-17% in adults in Germany between 1992-2008 
[153;194]. Serotype 14 was the second most common serotype identified in IPD cases after 
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serotype 19A in children <5 years, before PCV7 introduction in China [195]. Serotypes 6B, 19F 
and 23F were found to be significantly associated with paediatric patients compared to the adult 
age groups in the US and Germany prior PCV7 introduction [153;196].  
 
In individuals ≥5 years, serotype 1 was predominant, followed by serotypes 19A, 4, 6A, 23F and 
12F. The high burden of IPD due to serotype 1 in older children is also prevalent in other African 
regions [51;197;198] and other non-African regions. Serotype 19A, which is the leading serotype 
in most countries post introduction of PCV7 in many regions [145-147;149], was the second most 
common serotype in older children and adults. 
 
Although in our study for children <5 years, serotype 1 was the 7
th
 most common serotype 
identified and serotype 19A was the 4
th
 most common serotype identified, the burden of IPD due 
to these serotypes is still substantial. These serotypes causing invasive disease are not included in 
PCV7; however, serotypes 1 and 19A have subsequently been included in the PCV13 
formulation. Another PCV13 serotype, serotype 5, which is predominant in other African 
countries [50;64;197;198], was not found to be common amongst South African invasive 
pneumococci in both children and adults.  
 
This study was conducted during early introduction of PCV7 and further studies are required to 
monitor changes which may occur as a result of the vaccine. The difference in serotype 
distribution by age group supports the fact that paediatric serotypes differ from adult serotype 
distribution. Year 2010 was a transition year for PCV7 introduction in SA, and comparison 
between countries with post-vaccine serotype distributions might not provide ideal comparisons 
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amongst countries. However, previous serotype distribution from IPD surveillance in SA (2007-
2009), shows no change in the serotype distribution in all ages in 2010, thus data from pre-
vaccine introduction in different countries is more appropriate for comparisons.  
 
Molecular detection and serotyping of pneumococcal disease in paediatric empyema added useful 
information for estimating the burden of this complication in South African children. The 
pneumococcus was the leading pathogen detected among the three pathogens studied. The C-PCR 
assay could assign a serotype to a small proportion (29%) of specimens before it was 
discontinued for these specimens (due to low yield on specimens with lytA Ct-value of >26). The 
RT-PCR assay increased the serotype yield to 95%.  
 
Pneumonia complicated with empyema has been increasing in countries with routine PCV7 
utilisation, with non-vaccine serotypes being predominant [64;177-180;182;197;199]. In the 
PCV7 era, S. pneumoniae remains the leading cause of pleural empyema in children [199]. In this 
study, pneumococci from pleural fluid specimens were found to be of serotypes 6A/B, 19A, 23F, 
1 and 14. All serotypes identified, except 19A and 1 are PCV7 types. However, this study only 
reflects one hospital in SA (Red Cross Children‟s Hospital), and one group of children with this 
syndrome (those who received treatment and were enrolled in the study). The burden and 
aetiology of empyema in SA needs to be explored further using a larger collection of samples. 
However, available data suggest that PCV7 serotypes constitute a large proportion, 72% (13/18) 
of pneumococcal empyema cases in South African children before PCV7 introduction. This study 
was initiated in September 2009, and some enrolled children were eligible to receive the PCV7, 
while the majority were not. However, vaccination status was not recorded for this study. The 
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rollout of PCV7 was slow in some provinces in SA, and it is unlikely that the children who 
participated in this empyema study were vaccinated. Serotype distribution post vaccine 
introduction in vaccinated children is yet to be explored. This is the first study to our knowledge 
in SA on the aetiology and pneumococcal serotypes associated with pleural empyema.  
 
The historically empyema-associated serotypes in children are PCV7 serotypes, and serotypes 1 
and 3 [199]. In addition to the non-PCV7 serotypes listed above, serotypes 7A and 7F have 
emerged as serotypes associated with empyema complication [200]. Serotypes 1 and 19A were 
also prevalent in paediatric empyema cases identified in other parts of the world 
[180;181;201;202]. Serotypes 3 and 7F were not identified in SA for the study period. However, 
the data from this study and other studies described suggest PCV7 would be adequate for the 
majority of paediatric empyema cases, but PCV13 could further decrease the burden of this 
disease.  
 
The RT-PCR assay was applied to the serotyping of SARI blood specimens that were PCR-
positive for pneumococcal DNA. This is important as it provides information on the 
pneumococcal serotypes causing severe respiratory illness in SA. A serotype/serogroup was 
assigned to 53% of the specimens. A limitation of this assay on these specimens was that 
majority had high Ct-values, some even at the border of the cut-off for lytA positivity i.e. 39-40. 
Hence it is possible serotypes of some specimens with very high lytA Ct- values of around 38-40 
might have been missed. 
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The predominant serotypes identified in SA amongst hospitalised pneumonia cases; serotypes 
19A, 1, 6A/B and 19BF were common in other countries in children ≤5 years pre PCV usage. In 
Japan, the most common serotypes identified in hospitalised children <5 years were serotypes 6B, 
23F and 19A in both IPD and pneumonia cases [203;204]. Similarly in China, serotypes 19F, 
19A and 6B were predominant in hospitalised children <5 years with pneumonia [205]. With 
routine use of PCV7 and PCV13 in SA, serotype distribution amongst all age group is likely to 
change due to vaccine pressure, as has been observed in countries with long-term PCV usage 
[103;206]. 
 
Prior to 2010, no molecular based techniques for serotyping of pneumococcal-positive culture-
negative samples were available in SA. Although the overall serotype distribution was similar 
using either serotyping assay for all age groups, a significantly lower proportion of PCV7 
serotypes in culture-negative samples (36%) compared to culture-positive samples (43%; p=0.02) 
was observed. Although overall, no serotype differences were noted among the most common 
serotypes, the prevalence of PCV7 serotypes was less than in the culture-negative sample and this 
need to be explored further.  
 
Serotyping data from the SARI study specimens was used to assess the early effectiveness of 
PCV7 on severe pneumonia. This was possible as vaccine history was recorded as part of the 
study. A decrease in PCV7 serotypes among children eligible for vaccination was observed from 
2009 to 2010. There was a consistent decrease in PCV7 serotypes with an increase in the number 
of doses received. PCV7 serotypes accounted for 33%, 18% and 11% in children who received 0, 
1, or 2-3 doses, respectively (p=0.45). A limitation of this study is that the number of cases was 
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small, and continued SARI surveillance in the post PCV era will provide additional data on 
vaccine effectiveness against severe pneumonia cases.  
 
The reduction in the incidence of lytA positivity and PCV7 serotypes in vaccinated children 
cannot be attributed to PCV7 introduction alone. Highly active anti-retroviral therapy (HAART) 
was scaled up in 2003 in SA. In HIV-seropositive children, a decline in IPD burden, pneumonia 
hospitilisation and IPD-associated mortality was observed in children <2 years who were on the 
HAART program [77]. Recent studies show no evidence of reduction of IPD burden in HIV-
seropositive adults on HAART [207]. 
 
Detection of cases of multiple carriage are important in nasopharyngeal carriage models. In 2006 
a S. pneumoniae carriage project, known as PneumoCarr, was established to collect data on 
nasopharyngeal colonisation in children globally. The project aimed to develop guidelines for 
measuring vaccine efficacy using colonisation rather than disease or hospitalisation episodes as 
endpoints in clinical trials for future pneumococcal vaccine licensure. This would be less time-
consuming and more cost-effective when introducing new pneumococcal vaccines [208] and the 
preliminary results showed that carriage acquisition can be used as an endpoint in vaccine 
efficacy studies, using correct models [209]. The PneuCarriage project is a global project 
established to identify the best method to detect multiple serotypes in colonisation episodes by 
comparing over 20 different methods to be used in both well-equipped and poor-resourced 
laboratory settings [210]. Although this study is on-going, preliminary data indicate that the PCR-
based serotyping assays were more sensitive for detecting carriage of multiple serotypes when 
compared with other serotyping techniques [211;212].  
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Through this study we have been able to determine the early impact of PCV7 on pneumococcal 
disease in the country. Molecular serotyping will continue to be a useful tool to monitor serotype 
distribution and changes that may occur as PCV13 usage increases. 
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5 Conclusion 
PCR-based serotyping assays added 8% of serotyping data to the national IPD surveillance, thus 
enhancing the strength of the national IPD surveillance in SA. This is due to the ability of 
molecular methods to determine serotypes in specimens for which no bacterial cultures were 
available and for which serotyping data would not have otherwise been obtained. The ability to 
determine serotype for culture-negative clinical specimens will enable a more accurate 
assessment of vaccine effectiveness to be made.  
Based on the results of this study, PCR-based serotyping assays are recommended for other 
developing countries and low resourced settings with a high prevalence of pneumococcal disease. 
PCR assays are less subjective, less laborious and less time-consuming than the Quellung 
reaction.  
The early impact of PCV7 was assessed using serotyping data from this study. Although the 
numbers are small, there was evidence from the SARI surveillance study of the 2+1 dose being 
effective against vaccine-type disease, although more data are needed to test statistical 
significance. The introduction of PCV13 in SA, which was initiated in May 2011, is expected to 
have a positive public health impact on IPD. The leading serotypes in 2010 not included in the 
current PCV7 formulation identified were serotypes 1 and 19A for all age groups. Inclusion of 
these serotypes in PCV13 is therefore expected to be beneficial in this country. Serotype 
monitoring in both cultures and culture-negative samples, using low cost, fast methods is of 
utmost importance to monitor vaccine impact in the targeted age groups and the herd impact in 
the adult populations.  
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6 Appendices 
6.1 Appendix A: Preparation of reagents for conventional PCR 
Preparation of dNTP‟s from100 mM stock 
c1v1=c2v2 
100 mM X v1=5 mM X 1 ml 
v1=0.05 ml  
Add 50 µl of each dNTP (dATP, dTTP, dCTP and dGTP) to 800 µl of sterile dH20 to make up l 
ml of 5 mM working solution 
Preparation of 100 µM primers from 80 nmol stock  
Concentration =mol/v 
To prepare a 100 µM stock solution:  
100 µM= 80 nmol/v 
v=800 µl  
Add 800 µl of sterile dH20 to the lyophilised primers to make up a 100 µM stock solution 
Preparation of 10 µM primer working solution from 100 µM stock solution (For Amplitaq Gold 
DNA polymerase) 
c1v1=c2v2 
100 µM X v1=10 µM X 1000 µl 
v1=100 µl  
Add 100 µl from the stock solution and 900 µl of sterile dH20 
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Preparation of 25 µM primer working solution from 100 µM stock solution (for Qiagen Master 
Mix)  
c1v1=c2v2 
100 µM X v1=25 µM X 1000 µl 
v1=250 µl 
Add 250 µl from the stock solution to 750 µl of sterile dH20 
Storage of primers = -20˚C 
6.2 Appendix B: Preparation for reagents for RT-PCR 
Preparation of primers stock solution 
Concentration =mol/volume 
To prepare a 100 µM stock solution:  
100 µM= 80 nmol/v 
v=800 µl 
Add 800 µl of sterile dH20 to the lyophilised primers to make up a 100 µM stock solution 
 
Preparation of 10 µM primer working solution from 100 µM stock solution 
c1v1=c2v2 
100 µM X v1=10 µM X 1000 µl 
v1=100 µl  
Add 100 µl from the stock solution and 900 µl of sterile dH20
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Preparation of 5 µM probe working solution from 100 µM stock solution 
c1v1=c2v2 
100 µM X v1=5 µM X 400 µl 
v1=20 µl  
Add 20 µl from the stock solution to 380 µl of sterile dH20 to make up a 400 µl working solution 
Storage of primers and probes = -20˚C 
6.3 Appendix C: Agarose gel electrophoresis 
10X TAE buffer (Tris-acetate-EDTA) 
Volume/Mass Component 
96.8 g Tris base 
11.42 ml Acetic acid (glacial) 
14.88 g EDTA 
Adjust volume to 2 L using sterile dH20 
To prepare a running buffer, dilute 10X solution to get a 1X concentration i.e. add 100 ml of 10X 
TAE buffer to 900 ml of sterile dH20 
 
0.25% Bromophenol blue 
Mass Component 
0.25 g Bromophenol blue 
40 g Sucrose 
Dissolve in 100 ml of sterile dH20
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Ethidium bromide (10 mg/ml) 
Volume/mass Component 
1 g Ethidium bromide 
100 ml Sterile dH2O 
Storage of TAE buffer, ethidium bromide and bromophenol blue = +4˚C 
 
Saekem LE Agarose gel (2%) 
Volume/mass Component 
2.6 g Saekem LE agarose 
130 ml sterile dH20 
Boil the solution until all agarose has dissolved and cool down to 50˚C before adding the 
ethidium bromide. Pour the agarose solution immediately into the gel casting equipment and 
insert the appropriate comb while still liquid. After the gel has solidified, remove the combs and 
add 1X TAE running buffer.  
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6.4 Appendix D: Identification of Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae by real-time 
PCR assay.  
Table 10. Primer and probe sequences and final concentrations used for simultaneous detection of Haemophilus influenzae, Neisseria 
meningitidis and Streptococcus pneumoniae by real-time PCR [187] 
 
Organism (target)  Primer Primer/Probe sequence 5’-3’ Working conc. 
(µM) 
Final conc. 
(nM) 
N. meningitidis (ctrA) Forward 
Reverse 
Probe 
TGTGTTCCGCTATACGCCATT 
GCCATATTCACACGATATACC 
AACCTTGAGCAA"T"CCATTTATCCTGACGTTCT 
5‟FAM; 3‟SpC6; “T” BHQ1 
7.5 
22.5 
2.5 
300 
900 
100 
H. influenzae (hpd) Forward 
Reverse 
Probe 
AGATTGGAAAGAAACACAAGAAAAAGA 
CACCATCGGCATATTTAACCACT 
AAACATCCAATCG"T"AATTATAGTTTACCCAATAACCC 
5‟ HEX; 3‟SpC6; ”T” BHQ1 
7.5 
2.5 
5 
300 
100 
200 
S. pneumoniae (lytA) Forward 
Reverse 
Probe 
ACGCAATCTAGCAGATGAAGCA 
TCGTGCGTTTTAATTCCAGCT 
TGCCGAAAACGC"T"TGATACAGGGAG 
5‟Cy5; 3‟SpC6; ”T” BHQ2 
5 
5 
5 
200 
200 
200 
Note: quencher moved from 3‟end to internal position designated as”T”. 
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6.5 Appendix E: Primer sequences and reactions for conventional PCR assay 
 
Table 11. Primers used in the conventional sequential multiplex PCR assay  
Primer pair Primer sequence (5´-3´) Product 
Size(bp) 
1-f 
1-r 
CTC TAT AGA ATG GAG TAT ATA AAC TAT GGT TA 
CCA AAG AAA ATA CTA ACA TTA TCA CAA TAT TGG C 
280 
3-f 
3-r 
ATG GTG TGA TTT CTC CTA GAT TGG AAA GTA G  
CTT CTC CAA TTG CTT ACC AAG TGC AAT AAC G 
371 
4-f 
4-r 
CTG TTA CTT GTT CTG GAC TCT CGA TAA TTG G 
GCC CAC TCC TGT TAA AAT CCT ACC CGC ATT G 
430 
5-f 
5-r 
ATA CCT ACA CAA CTT CTG ATT ATG CCT TTG TG 
GCT CGA TAA ACA TAA TCA ATA TTT GAA AAA GTA TG 
362 
6A/B/C-r 
6A/B/C-f 
AAT TTG TAT TTT ATT CAT GCC TAT ATC TGG 
TTA GCG GAG ATA ATT TAA AAT GAT GAC TA 
250 
7F-f 
7F-r 
CCT AGC GGA TAT AAA ATT ATT TTT GAG 
CAA ATA CAC CAC TAT AGG CTG TTG AGA CTA AC 
826 
7C(7B/40)-f 
7C(7B/40)-r 
CTA TCT CGA TCA TCT ATT GTT AAA GTT TAC GAC GGG GAA CAT 
AGA TGT TGA GAC ATC TTT TGT AAT TTC 
260 
8-f 
8-r 
GAT GCC ATG AAT CAA GCA GTG GCT ATA AAT C 
ATC CTC GTG TAT AAT TTC AGG TAT GCC ACC 
201 
9V-f 
9V-r 
CTT CGT TAG TTA AAA TTC TAA ATT TTT CTA AG 
GTC CCA ATA CCA GTC CTT GCA ACA CAA G 
753 
9N /L-f 
9N/L-r 
GAA CTG AAT AAG TCA GAT TTA ATC AGC 
ACC AAG ATC TGA CGG GCT AAT CAA T 
516 
10A-f 
10A-r 
GGT GTA GAT TTA CCA TTA GTG TCG GCA GAC 
GAA TTT CTT CTT TAA GAT TCG GAT ATT TCT C 
628 
11A/(11D)-f 
11A/(11D)-r 
GGA CAT GTT CAG GTG ATT TCC CAA TAT AGT G 
GAT TAT GAG TGT AAT TTA TTC CAA CTT CTC CC 
463 
12F(12A/44/46)-f 
12F(12A/44/46)-r 
GCA ACA AAC GGC GTG AAA GTA GTT G 
CAA GAT GAA TAT CAC TAC CAA TAA CAA AAC 
376 
14-f 
14-r 
CTT GGC GCA GGT GTC AGA ATT CCC TCT AC 
GCC AA ATA CTGACA AAG CTA GAA TAT AGC C 
208 
15A/(15F)-f AAT AGT ACA GCT GCT GGA ATA TCT CTT C 436 
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15A/(15FF)-r GAT CTAGTG AAC GTA CTA TTC CAA AC 
15B/C-f 
15B/C-r 
TTG GAA TTT TTT AAT TAG TGG CTT ACC TA 
CAT CCG CTT ATT AAT TGA AGT AAT CTG AAC C 
496 
16F-f 
16F-r 
CTG TTC AGA TAG GCC ATT TAC AGC TTT AAA TC 
CAT TCC TTT TGT ATA TAG TGC TAG TTC ATC C 
988 
17F-f 
17F-r 
TTC GTG ATG ATA ATT CCA ATG ATC AAA CAA GAG 
GAT GTA ACA AAT TTG TAG CGA CTA AGG TCT GC 
693 
18-f 
18-r 
TTC GTG ATG ATA ATT CCA ATG ATC AAA CAA GAG 
TTA TCT GTA ACA A AC CAT ATC AGC ATC TGA AAC 
573 
19A-f 
19A-r 
CTT AGT CCT GTT TTA GAT TTA TTT GGT GAT GT 
GAG CAG TCA ATA AGA TGA GAC GAT AGT TAG 
478 
19F-f 
19F-r 
GTT AAG ATT GCT GAT CGA TTA ATT GAT ATC C 
GTA ATA TGT.CTT TAG GGC GTT TAT GGC GAT A 
304 
20-f 
20-r 
GAT CAA GAG TTT TTC ACC TGA CAG CGA GAA G 
CTA AAT TCC TGT AAT TTA GCT AAA ACT CTT ATC 
514 
22F/A-f 
22F/A-r 
GAG TAT AGC CAG ATT ATG GCA GTT TTA TTG TC 
CTC CAG CAC TTG CGC TGG AAA CAA CAG ACA AC 
643 
23A-f 
23A-r 
TAT TCT AGC AAG TGA CGA AGA TGC G 
CCA ACA TGC TTA AAA ACG CTG CTT TAC 
722 
23F-f 
23F-r 
GTA ACA GTT GCT GTA GAG GGA ATT GGC TTT TC 
CAC AAC ACC TAA CAC ACG ATG GCT ATA TGA TTC 
384 
31-f 
31-r 
GGA AGT TTT CAA GGA TAT GAT AGT GGT GGT GC 
CCG AAT AAT ATA TTC AAT ATA TTC CTA CTC 
701 
33F/(33A/37)-f 
33F/(33A/37)-r 
GAA GGC AAT CAA TGT GAT TGT GTC GCG 
CTT CAA AAT GAA GAT TAT AGT ACC CTT CTA C 
338 
34-f 
34-r 
GCT TTT GTA AGA GGA GAT TAT TTT CAC CCA AC 
CAA TCC GAC TAA GTC TTC AGT AAA AAA CTT TAC 
408 
35B-f 
35B-r 
GCT TTT GTA AGA GGA GAT TAT TTT CAC CCA AC 
CAA TCC GAC TAA GTC TTC AGT AAA AAA CTT TAC 
677 
35F/(47F)-f 
35F/(47F)-r 
GAA CAT AGT CGC TAT TGT ATT TTA TTT AAA GCA A GAC TAG 
GAG CAT TAT TCC TAG AGC GAG TAA ACC 
517 
38/(25F)-f 
38/(25F)-r 
CGT TCT TTT ATC TCA CTG TAT AGT ATC TTT ATG 
ATG TTT GAA TTA AAG CTA ACG TAA CAA TCC 
574 
cpcA-f 
cpsA-r 
GCA GTA CAG CAG TTT GTT GGA CTG ACC 
GAA TAT TTT CAT TAT CAG TCC CAG TC 
160 
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Table 12. Composition of the six sequential multiplex reactions of the conventional serotyping 
PCR assay used in this study. 
a)  
Reaction 1 
Initial 
concentration 
Final 
concentration 
Volume  
(25 µl PCR) 
2X PCR Master mix (Qiagen Multiplex 
PCR kit)  
2X 1X 12.5µl 
CPSA-F 25 µM 0.1 µM 0.1 µl 
CPSA-R 25 µM 0.1 µM 0.1 µl 
14-F 25 µM 0.3 µM 0.3 µl 
14-R 25 µM 0.3 µM 0.3 µl 
6A/B/C-R 25 µM 0.3 µM 0.3 µl 
6A/B/C-F  25 µM 0.3 µM 0.3 µl 
23F-F  25 µM 0.5 µM 0.5 µl 
23F-R  25 µM 0.5 µM 0.5 µl 
19A-F  25 µM 0.3 µM 0.3 µl 
19A-R  25 µM 0.3 µM 0.3 µl 
9V-F 25 µM 0.5 µM 0.5 µl 
9V-R 25 µM 0.5 µM 0.5 µl 
DNA     5 µl 
dH2O     6.5 µl 
 
b)  
Reaction 2 
Initial 
Concentration 
Final 
Concentration 
Volume  
(25 µl PCR) 
2X PCR Master mix (Qiagen Multiplex 
PCR kit) 
2X 1X 12.5µl 
CPSA-F  25 µM 0.1 µM 0.1 µl 
CPSA-R 
  
25 µM 0.1 µM 0.1 µl 
19F-F  25 µM 0.5 µM 0.5 µl 
19F-R 25 µM 0.5 µM 0.5 µl 
3-F 25 µM 0.3 µM 0.3 µl 
3-R 25 µM 0.3 µM 0.3 µl 
15B/C-F 25 µM 0.3 µM 0.3 µl 
15B/C-R  25 µM 0.3 µM 0.3 µl 
18-F 25 µM 0.3 µM 0.3 µl 
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18-R  25 µM 0.3 µM 0.3 µl 
10A-F  25 µM 0.5 µM 0.5 µl 
10A-R  25 µM 0.5 µM 0.5 µl 
7F-F  25 µM 0.7 µM 0.7 µl 
7F-R  25 µM 0.7 µM 0.7 µl 
DNA 
  
    2 µl 
dH2O 
  
    5.1 µl 
 
c)  
Reaction 3 
Initial 
concentration 
Final 
concentration 
Volume  
(25 µl PCR) 
2X PCR Master mix (Qiagen Multiplex 
PCR kit)  
2X 1X 12.5 µl 
CPSA-F  25 µM 0.1 µM 0.1 µl 
CPSA-R 
  
25 µM 0.1 µM 0.1 µl 
1-F  25 µM 0.3 µM 0.3 µl 
1-R  25 µM 0.3 µM 0.3 µl 
5-F 25 µM 0.3 µM 0.3 µl 
5-R  25 µM 0.3 µM 0.3 µl 
11A-F 25 µM 0.3 µM 0.3 µl 
11A-R  25 µM 0.3 µM 0.3 µl 
9L/N-F  25 µM 0.5 µM 0.5 µl 
9L/N-R 25 µM 0.5 µM 0.5 µl 
17F-F  25 µM 0.5 µM 0.5 µl 
17F-R  25 µM 0.5 µM 0.5 µl 
DNA 
  
    2 µl 
dH2O 
  
    6.5 µl 
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d)  
Reaction 4 
Initial 
concentration 
Final 
concentration 
Volume  
(25 µl PCR) 
2X PCR Master mix (Qiagen Multiplex 
PCR kit)  
2X 1X 12.5 µl 
CPSA-F  25 µM 0.1 µM 0.1 µl 
CPSA-R 
  
25 µM 0.1 µM 0.1 µl 
7C-F  25 µM 0.3 µM 0.3 µl 
7C-R  25 µM 0.3 µM 0.3 µl 
12F-F  25 µM 0.5 µM 0.5 µl 
12F-R  25 µM 0.5 µM 0.5 µl 
4-F  25 µM 0.3 µM 0.3 µl 
4-R  25 µM 0.3 µM 0.3 µl 
38-F 25 µM 0.3 µM 0.3 µl 
38-R  25 µM 0.3 µM 0.3 µl 
23A-F 25 µM 0.5µM 0.5 µl 
23A-R 25 µM 0.5 µM 0.5 µl 
DNA 
  
    2 µl 
dH2O 
  
    6.5 µl 
 
e)  
Reaction 5 
Initial 
concentration 
Final 
concentration 
Volume  
(25 µl PCR) 
2X PCR Master mix (Qiagen Multiplex 
PCR kit)  
2X 1X 12.5 µl 
CPSA-F  25 µM 0.1 µM 0.1 µl 
CPSA-R 25 µM 0.1 µM 0.1 µl 
8 25 µM 0.2 µM 0.2 µl 
8 25 µM 0.2 µM 0.2 µl 
2-F 25 µM 0.3 µM 0.3 µl 
2-R 25 µM 0.3 µM 0.3 µl 
34-F 25 µM 0.3 µM 0.3 µl 
34-R 25 µM 0.3 µM 0.3 µl 
20-F 25 µM 0.3 µM 0.3 µl 
20-R 25 µM 0.3 µM 0.3 µl 
22F-F  25 µM 0.5 µM 0.5 µl 
22F-R  25 µM 0.5 µM 0.5 µl 
31-F 25 µM 0.5 µM 0.5 µl 
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31-R  25 µM 0.5 µM 0.5 µl 
DNA 
  
    2 µl 
dH2O     6.1 µl 
 
f)  
Reaction 6 
Initial 
Concentration 
Final 
Concentration 
Volume  
(25 µl reaction) 
2X PCR Master mix (Qiagen Multiplex 
PCR kit)  
2X 1X 12.5 µl 
CPSA-F  25 µM 0.1 µM 0.1 µl 
CPSA-R 
  
25 µM 0.1 µM 0.1 µl 
33F-F  25 µM 0.3 µM 0.3 µl 
33F-R  25 µM 0.3 µM 0.3 µl 
15A-F 25 µM 0.3 µM 0.3 µl 
15A-R  25 µM 0.3 µM 0.3 µl 
35F-F  25 µM 0.3 µM 0.3 µl 
35F-R  25 µM 0.3 µM 0.3 µl 
35B-F  25 µM 0.5 µM 0.5 µl 
35B-R  25 µM 0.5 µM 0.5 µl 
16F-F  25 µM 0.5 µM 0.5 µl 
16F-R  25 µM 0.5 µM 0.5 µl 
DNA 
  
    2 µl 
dH2O 
  
    6.5 µl 
 
 
Chapter 6. Appendices 
116 
 
6.6 Appendix F: Primer sequences and reactions for the real-time PCR assay 
Table 13. Primers used for the determination of 22 serogroup/types by real-time-PCR  
Serotype Primer sequence (5´-3´) Probe sequence Dye-label 
1-f 
1-r 
CGT GCG GTA ATT GAA GCT ATG A 
TGT GGC CCC AGC AAC TCT 
TGCTTGCCCTTGTATAGGGT FAM 
3-f 
3-r 
GGT CAG CAG AAA GTA TGC ATT GG 
TCG TTT ATC CAG GGT CTG ATG A 
TATTGGATGTGGTTTATCGTGAAGA VIC 
4-f 
4-r 
TGG GAT GAC ATT TCT ACG CAC TA 
CCG TCG CTG ATG CTT TAT CA 
TCCTATTGGATGGTTAGTTGGTGA FAM 
5-f 
5-r 
TTA CGG GAG TAT CTT AT GTC TTT AATGG 
CAG CAT TCC AGT AGC CTA AAA CTA GA 
TTGTCTCAGCAACTCTATTTGGCTGTGGG VIC 
6-f 
6-r 
AAG TTT GCA CTA GAG TAT GGG AAG GT 
ACA TTA TGT CCR TGT CTT CGA TAC AAG 
TGTTCTGCCCTGAGCAACTGG VIC 
6C/D-f TTG GGA TGA TTG GTC GTA TTA G CCA CGC AAT TCG CCA TC FAM 
6C/D-r CTC TTC AAT TAG TTC TTC AGT TCG   
7A/F-f 
7A/F-r 
GAT GGC ATG TGG CAA ACC A 
TTT GCC CTC CTT AAT CAT TTC AC 
TTGGCTATCGGCATGGTGGT VIC 
8-f 
8-r 
CCA CTC ATC AGT TTC CCA TAT GTT T 
TCA ATA ATT GAA GAA GCG AAC GTT 
TGATGGCAGATGGGTTGGGACGAG VIC 
9V/A-f 
9V/A-r 
TGG AAT GGG CAA AGG GTA GTA 
TCG GTT CCC CAA GAT TTT CTC 
TTAATCATGCTAACGGCTCATCGA FAM 
10A/B-f 
10A/B-r 
CCT CTC CTA TCA ACT ATT ACT CAT TAT ACT ACC T 
AAT AAC CAT AAG TCC CTA GAT CAT TCA AAG 
TCATTACAACTCCCTATGTGACACGGGTCTTTT VIC 
12A/B/F-f 
12A/B/F-r 
GAT TAT TCG CTT GCC TCT TCA TG 
ATA GCC GAA ATA AGC TTT CCA GAA 
ATTTGTAAGCGGACCGTGCGATT FAM 
14-f CGA CTG AAA TGT CAC TAG GAG AAG AT TGTCATTCGTTTGCCAATACTTGATGGTCTC VIC 
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14-r AAT ACA GTC CAT CAA TTA CTG CAA TAC TC 
15-f 
15-r 
TTG AAT CAG GTA GAT TGA TTT CTG CTA 
CTC TAG GAA TCA AAT ACT GAG TCC TAAT GA 
CTCCGGCTTTTGTCTTCTCTGT FAM 
18B/C-f 
18B/C-r 
CCT GTT GTT ATT CAC GCC TTA CG 
TTG CAC TTC TCG AAT AGC CTT ACTC 
AACCGTTGGCCCTTGTGGTGGA FAM 
19A-f 
19A-r 
TTC GAC GAC GTA TCA GCT TCA 
TCA TTG AGA GCC TTA ACC TCT TCA 
ACCCAAAACGGTTGACGCATTATACT VIC 
19B/F-f 
19B/F-r 
GGT CAT GCG AGA TAC GAC AGA A 
TCC TCA TCA GTC CCA ACC AAT T 
ACCTGAAGGAGTAGCTGCTGGAACGTTG VIC 
20-f 
20-r 
AAA GAT ACT GGC TGA GGA GCT ATC TAT T 
AGT CAA AAG TAC TCA ACC ATT CTG ATA TAT TC 
AGGATAAGGTCTACTTTGTGGGAGTTC VIC 
22A/F-f 
22A/F-r 
CTA TTA AAT AAC CCA TTG GAA TTG AAA CG 
TCG CAA TTG AAG ACC ACA TAA ACTG 
TCCGTAATTCGCTTATGGGCACATTCTCCA VIC 
23F-f 
23F-r 
TGC TAT TTG CGA TCC TGT TCA T 
AGA GCC TCC GTT GTT TCG TAA A 
TTTCTCCGGCATCAAACGTTAAG FAM 
33A/F-f 
33A/F-r 
CGA GAG AGA ATA TGA GGG AAT TGT TA 
TCT CAA TCC CCG CAT TTA CTG 
AGGAAAACTGTGGTCACGGTTCG FAM 
35B-f 
35B-r 
GCA TGG AGG TGG AGC ATA CA 
TGT AAA GAC TGC ACA ACT CGA TAT AAA A 
CAATTTAAACAATATTAGTAAAGCGCAGGTCAAGCAAA FAM 
38-f 
38-r 
GTC TTA CGT AGA ACC TCT CTG GAT GA 
TGG TCC TAC AAG CGA CAT GTG 
TTGCCACAGATTTGGAATATTTTGGTCGG FAM 
cpsA-f 
cpsA-r 
GCT CCT AAG ACG TCT AAG AAT CAG TCT 
CGA CAC CGA ACT AAT AGG ACC AT 
TCTATGTTAGTGGAATTGAC NED 
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Table 14. Composition of the eleven duplex reactions of the real-time PCR assay 
Reactions Serotypes Dye label Final conc. of primers and probe 
Reaction 1 
19A 
18A/B/C 
VIC 
FAM 
400nM 
200nM 
Reaction 2 
3 
1 
VIC 
FAM 
400nM 
200nM 
Reaction 3 
14 
4 
VIC 
FAM 
400nM 
200nM 
Reaction 4 
6 
6C/D 
VIC 
FAM 
400nM 
200nM 
Reaction 5 
5 
23F 
VIC 
FAM 
400nM 
2500nM 
Reaction 6 
8 
12A/B/F 
VIC 
FAM 
400nM 
200nM 
Reaction 7 
7A/F 
15 
VIC 
FAM 
400nM 
200nM 
Reaction 8 
19B/F 
33A/F/37 
VIC 
FAM 
400nM 
200nM 
Reaction 9 
22A/F 
9 
VIC 
FAM 
400nM 
200nM 
Reaction 10 
10A/B 
38/25 
VIC 
FAM 
400nM 
200nM 
Reaction 11 
20 
35B 
VIC 
FAM 
400nM 
200nM 
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6.7 Appendix G: Primer sequences and reactions for serogroup 6 differentiation by 
conventional PCR.  
Table 15. Primers used in the determination of serogroup 6 serotypes (6A, 6B, 6C and 6D) 
Primer pair Serotype(s) 
detected 
Target 
gene 
Primer sequence (5´-3´) Product Size 
6-F 6A, 6B, 6C, 6D wciP TTA GCG GAG ATA ATT TAA AAT GAT 
GAC TA 
250 bp 
6-R 6A, 6B, 6C, 6D wciP AAT TTG TAT TTT ATT CAT GCC TAT 
ATC TGG 
wciNβS1  wciNβ ATC TCT AAA TCT GAA TAT GAA GCG 
GCT CAA TC 
359 bp 
wciNβA2 
 
6C, 6D wciNβ GAA CTG AGC TAA ATA ATC CTC TGG 
ATT ATC CAC C 
wciNβS2  wciNβ CGG CTC AAT CTT TAA AAA TAC CCC 
TTA AGA AAT TGA C 
308 bp 
wciNβA1 
 
6C, 6D wciNβ CCA CCC ACC CTG TTA TAA AAA ATG 
AGC TTC G 
wciP584aS  wciP AAG ATT ATT TAT ATA TAG AAA AAC 
TGT CTC ATG ATA A 
155 bp 
wciP-r 6B wciP GCG GAG ATA ATT TAA AAT GAT GAC 
TAG TTG 
a 
S, sense; A, antisense; r, reverse. 
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Table 16. Preparation of reaction mixes for differentiating serogroup 6 serotypes using a single 
multiplex conventional PCR reaction to detect all serogroup 6 serotypes (a) and two duplex 
reactions for individual detection of serogroup 6 serotypes (b & c).  
a)  
Reaction 1 
Initial 
concentration  
Final concentration 25 µl reaction 
2X PCR Master mix (Qiagen 
Multiplex PCR kit) 
2X 1X 12.5 µL 
6A/B/C-R  25 µM 0.3 µM 0.3 µl 
6A/B/C-F  25 µM 0.3 µM 0.3 µl 
6B-F (wciP584aS) 25 µM 0.7 µM 0.7 µl 
6B-R (wciP-r) 25 µM 0.7 µM 0.7 µl 
6C/D[wciNβS1]/ wciNβS2] 25 µM 0.5 µM 0.5 µl 
6C/D wciNβA2/ wciNβA1 25 µM 0.5 µM 0.5 µl 
DNA   2 µl 
dH2O   7.5 µl 
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b)  
Reaction 1 
Initial 
concentration  
Final concentration 25 µl reaction  
2X PCR Master mix (Qiagen 
Multiplex PCR kit) 
2X 1X 12.5 µl 
6A/B/C-R  25 µM 0.3 µM 0.3 µl 
6A/B/C-F  25 µM 0.3 µM 0.3 µl 
6B-F 25 µM 0.7 µM 0.7 µl 
6B-R  25 µM 0.7 µM 0.7 µl 
DNA   2 µl 
dH2O   8.5 µl 
 
c)  
Reaction 2 
Initial 
concentration 
Final concentration 25 µl reaction  
2X PCR Master mix (Qiagen 
Multiplex PCR kit) 
2X 1X 12.5 µl 
6A/B/C-R  25 µM 0. 3µM 0.3 µl 
6A/B/C-F  25 µM 0.3 µM 0.3 µl 
6C/D[wciNβS1]/ wciNβS2] 25 µM 0.5 µM 0.5 µl 
6C/D [wciNβA2/ wciNβA1] 25 µM 0.5 µM 0.5 µl 
DNA   2 µl 
dH2O   8.9 µl 
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6.8 Appendix H: Clearance certificate 
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